{
    "id": 10534,
    "name": "stomach cancer",
    "source": "DOID",
    "definition": "A gastrointestinal system cancer that is located_in the stomach. [url:http\\://cancergenome.nih.gov/cancersselected/stomach-esophagealcancer, url:http\\://en.wikipedia.org/wiki/Stomach]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        "4713",
        "10542",
        "10543",
        "10539"
    ],
    "termId": "DOID:10534",
    "evidence": [
        {
            "id": 453,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial that supported FDA approval, treatment with Cyramza (ramucirumab) in combination with Taxol (paclitaxel) increased progression-free and overall survival and improved quality of life compared to treatment with Taxol (paclitaxel) alone in patients with advanced gastric cancer (PMID:24706672).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1721,
                "therapyName": "Paclitaxel + Ramucirumab",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 200,
                    "pubMedId": 24706672,
                    "title": "Ramucirumab extends gastric cancer survival.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24706672"
                },
                {
                    "id": 15576,
                    "pubMedId": null,
                    "title": "Cyramza (ramucirumab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125477"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 502,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, selumetinib (AZD6244) inhibited growth of a gastric cancer cell line that requires MAP2K1 Q56P and inhibited phosphorylation of ERK in these cells (PMID: 22327936).",
            "molecularProfile": {
                "id": 584,
                "profileName": "MAP2K1 Q56P"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 135,
                    "pubMedId": 22327936,
                    "title": "Oncogenic MAP2K1 mutations in human epithelial tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22327936"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 926,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In preclinical studies, Tykerb (lapatinib) demonstrated antiproliferative activity in HER2-amplified gastric cancer in cell assays and in xenograft models (PMID: 20179222).",
            "molecularProfile": {
                "id": 531,
                "profileName": "ERBB2 amp"
            },
            "therapy": {
                "id": 787,
                "therapyName": "Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 604,
                    "pubMedId": 20179222,
                    "title": "Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20179222"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 928,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ERBB2 (HER2)-specific cytotoxic T-cell lines generated from gastric cancer patients demonstrated activity against autologous ERBB2 (HER2)-expressing gastric cancer cells in culture (PMID: 9754653).",
            "molecularProfile": {
                "id": 1187,
                "profileName": "ERBB2 positive"
            },
            "therapy": {
                "id": 1404,
                "therapyName": "HER2 Vaccine",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 605,
                    "pubMedId": 9754653,
                    "title": "Identification of HER2/neu-derived peptide epitopes recognized by gastric cancer-specific cytotoxic T lymphocytes.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/9754653"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 939,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, second-line treatment using Tykerb (lapatinib) with paclitaxel demonstrated some efficacy in patients with HER2-positive advanced gastric cancer (PMID: 24868024).",
            "molecularProfile": {
                "id": 1187,
                "profileName": "ERBB2 positive"
            },
            "therapy": {
                "id": 1410,
                "therapyName": "Lapatinib + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 614,
                    "pubMedId": 24868024,
                    "title": "Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24868024"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 947,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Herceptin (trastuzumab) and Eloxatin (oxaliplatin) resulted in growth inhibition of ERBB2 (HER2)-positive gastric cancer cells in culture (PMID: 24300914).",
            "molecularProfile": {
                "id": 1187,
                "profileName": "ERBB2 positive"
            },
            "therapy": {
                "id": 1412,
                "therapyName": "Oxaliplatin + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 620,
                    "pubMedId": 24300914,
                    "title": "Trastuzumab and oxaliplatin exhibit a synergistic antitumor effect in HER2-postive gastric cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24300914"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1611,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RAD51C-deficient gastric cancer cells demonstrated increased sensitivity to Lynparza (olaparib) compared to cells over expressing RAD51C, and Lynparza (olaparib) treatment inhibited tumor growth in RAD51C-deficient gastric cancer cell line xenograft models (PMID: 23512992).",
            "molecularProfile": {
                "id": 2751,
                "profileName": "RAD51C loss"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1652,
                    "pubMedId": 23512992,
                    "title": "RAD51C-deficient cancer cells are highly sensitive to the PARP inhibitor olaparib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23512992"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1727,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Saracatinib (AZD0530) treatment resulted in stable disease in 23.5% (4/17) of patients with gastric cancer (PMID: 21400081).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 912,
                "therapyName": "Saracatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 1955,
                    "pubMedId": 21400081,
                    "title": "A phase II trial of the Src kinase inhibitor saracatinib (AZD0530) in patients with metastatic or locally advanced gastric or gastro esophageal junction (GEJ) adenocarcinoma: a trial of the PMH phase II consortium.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21400081"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 1773,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SAR125844 inhibited Met signaling leading to growth inhibition of MET amplified gastric cancer cell lines in culture and in xenograft models (PMID: 25504634).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 2159,
                "therapyName": "SAR125844",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2009,
                    "pubMedId": 25504634,
                    "title": "The selective intravenous inhibitor of the MET tyrosine kinase SAR125844 inhibits tumor growth in MET-amplified cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25504634"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2003,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial that supported FDA approval, treatment with Cyramza (ramucirumab) increased progression-free and overall survival in patients with advanced gastric cancer (PMID: 24094768).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 886,
                "therapyName": "Ramucirumab",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 2449,
                    "pubMedId": 24094768,
                    "title": "Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24094768"
                },
                {
                    "id": 15576,
                    "pubMedId": null,
                    "title": "Cyramza (ramucirumab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125477"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7569,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, treatment with AZD4547 resulted in a 33% (3/9) response rate in patients with FGFR2-amplified gastroesophageal cancer, and high-level amplification was associated with clinical response (PMID: 27179038).",
            "molecularProfile": {
                "id": 3147,
                "profileName": "FGFR2 amp"
            },
            "therapy": {
                "id": 654,
                "therapyName": "AZD4547",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6434,
                    "pubMedId": 27179038,
                    "title": "High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27179038"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 2580,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD4547 inhibited FGFR signaling, and decreased proliferation and induced cell-cycle arrest in gastric cancer cells with amplification and over expression of FGFR2 in culture (PMID: 22869148).",
            "molecularProfile": {
                "id": 3147,
                "profileName": "FGFR2 amp"
            },
            "therapy": {
                "id": 654,
                "therapyName": "AZD4547",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3319,
                    "pubMedId": 22869148,
                    "title": "Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22869148"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21006,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD4547 inhibited growth of a gastric cancer cell line harboring FGFR2 amplification in culture (PMID: 30045926).",
            "molecularProfile": {
                "id": 3147,
                "profileName": "FGFR2 amp"
            },
            "therapy": {
                "id": 654,
                "therapyName": "AZD4547",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18258,
                    "pubMedId": 30045926,
                    "title": "Acquired JHDM1D-BRAF Fusion Confers Resistance to FGFR Inhibition in FGFR2-Amplified Gastric Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30045926"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2581,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, gastric cancer cells with wild-type FGFR2 and ERBB2 (HER2) amplification were resistant to treatment with AZD4547 in culture (PMID: 22869148).",
            "molecularProfile": {
                "id": 9482,
                "profileName": "ERBB2 amp FGFR2 wild-type"
            },
            "therapy": {
                "id": 654,
                "therapyName": "AZD4547",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3319,
                    "pubMedId": 22869148,
                    "title": "Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22869148"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2719,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, gastric cancer xenograft models harboring KRAS mutations demonstrated decreased sensitivity to BAY1082439 in culture (AACR; 2015. Abstract nr 2674).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 666,
                "therapyName": "BAY1082439",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 3435,
                    "pubMedId": null,
                    "title": "Activity of BAY1082439, a balanced PI3Kalpha/beta inhibitor, in gastric cancer",
                    "url": "http://www.abstractsonline.com/plan/ViewAbstract.aspx?mID=3682&sKey=14323955-7e99-4856-aec7-b2f95e96b99b&cKey=5384c5ef-c9a4-49da-a50c-67bf77ceef19&mKey=19573a54-ae8f-4e00-9c23-bd6d62268424"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 2720,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BAY1082439 inhibited growth of gastric cancer cells harboring PIK3CA mutations in culture and xenograft models (AACR; 2015. Abstract nr 2674).",
            "molecularProfile": {
                "id": 429,
                "profileName": "PIK3CA mutant"
            },
            "therapy": {
                "id": 666,
                "therapyName": "BAY1082439",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3435,
                    "pubMedId": null,
                    "title": "Activity of BAY1082439, a balanced PI3Kalpha/beta inhibitor, in gastric cancer",
                    "url": "http://www.abstractsonline.com/plan/ViewAbstract.aspx?mID=3682&sKey=14323955-7e99-4856-aec7-b2f95e96b99b&cKey=5384c5ef-c9a4-49da-a50c-67bf77ceef19&mKey=19573a54-ae8f-4e00-9c23-bd6d62268424"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2738,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Buparlisib (BKM120) and Tyrphostin B42 (AG-490) worked synergistically to inhibit proliferation and induce apoptosis in gastric cancer cell lines harboring KRAS mutations in culture (PMID: 22159814).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 3019,
                "therapyName": "Buparlisib + Tyrphostin B42",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3447,
                    "pubMedId": 22159814,
                    "title": "NVP-BKM120, a novel PI3K inhibitor, shows synergism with a STAT3 inhibitor in human gastric cancer cells harboring KRAS mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22159814"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2739,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Buparlisib (BKM120) and Tyrphostin B42 (AG-490) worked synergistically to inhibit proliferation and induce apoptosis in gastric cancer cell lines harboring KRAS G12D in culture (PMID: 22159814).",
            "molecularProfile": {
                "id": 746,
                "profileName": "KRAS G12D"
            },
            "therapy": {
                "id": 3019,
                "therapyName": "Buparlisib + Tyrphostin B42",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3447,
                    "pubMedId": 22159814,
                    "title": "NVP-BKM120, a novel PI3K inhibitor, shows synergism with a STAT3 inhibitor in human gastric cancer cells harboring KRAS mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22159814"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2752,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Deguelin and Platinol (cisplatin) worked synergistically to inhibit growth of gastric cancer cells in culture (PMID: 25202376).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3022,
                "therapyName": "Cisplatin + Deguelin",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 3456,
                    "pubMedId": 25202376,
                    "title": "Synergistic antitumor effects of combined deguelin and cisplatin treatment in gastric cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25202376"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 2794,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD5363 inhibited growth in a patient-derived xenograft model of gastric cancer harboring a PIK3CA H1047R mutation (PMID: 24088382).",
            "molecularProfile": {
                "id": 1731,
                "profileName": "PIK3CA H1047R"
            },
            "therapy": {
                "id": 655,
                "therapyName": "Capivasertib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1081,
                    "pubMedId": 24088382,
                    "title": "The AKT inhibitor AZD5363 is selectively active in PI3KCA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to Taxotere.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24088382"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2799,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BKM120 suppressed growth of a gastric cancer cell line harboring PIK3CA and KRAS mutations in culture (PMID: 22159814).",
            "molecularProfile": {
                "id": 1630,
                "profileName": "KRAS mut PIK3CA mut"
            },
            "therapy": {
                "id": 680,
                "therapyName": "Buparlisib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3447,
                    "pubMedId": 22159814,
                    "title": "NVP-BKM120, a novel PI3K inhibitor, shows synergism with a STAT3 inhibitor in human gastric cancer cells harboring KRAS mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22159814"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2831,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RX-0201 prevented cell proliferation of stomach cancer cells (JASCO Annual Meeting Proceedings Vol 24, No 18S (June 20 Supplement), 2006: 13102).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 908,
                "therapyName": "RX-0201",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 3495,
                    "pubMedId": null,
                    "title": "Phase I study of RX-0201 in patients with advanced or metastatic solid tumors",
                    "url": "https://ascopubs.org/doi/abs/10.1200/jco.2006.24.18_suppl.13102"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 2833,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, a gastric cancer patient treated with CUDC-101 demonstrated a partial response for 57 days, in which the tumor regressed by 56% (PMID: 25107918).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1005,
                "therapyName": "CUDC-101",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 3496,
                    "pubMedId": 25107918,
                    "title": "Phase I first-in-human study of CUDC-101, a multitargeted inhibitor of HDACs, EGFR, and HER2 in patients with advanced solid tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25107918"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 2834,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human gastric cancer cells demonstrated sensitivity to JNJ-26483327 (PMID: 19584230).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1027,
                "therapyName": "JNJ-26483327",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 3497,
                    "pubMedId": 19584230,
                    "title": "Response prediction to a multitargeted kinase inhibitor in cancer cell lines and xenograft tumors using high-content tyrosine peptide arrays with a kinetic readout.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19584230"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 2839,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a human gastric cancer cell line harboring a KRAS mutation demonstrated resistance to Poziotinib (PMID: 21306821).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 1042,
                "therapyName": "Poziotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2314,
                    "pubMedId": 21306821,
                    "title": "Antitumor activity of HM781-36B, an irreversible Pan-HER inhibitor, alone or in combination with cytotoxic chemotherapeutic agents in gastric cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21306821"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2842,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, S-222611 inhibited cell growth, decreased phosphorylation of Egfr and Erbb2, and resulted in anti-tumor activity of human gastric cancer cells expressing EGFR and ERBB2 (HER2) both in culture and in cell line xenograft models (PMID: 24837299).",
            "molecularProfile": {
                "id": 2242,
                "profileName": "EGFR pos ERBB2 pos"
            },
            "therapy": {
                "id": 1048,
                "therapyName": "S-222611",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1835,
                    "pubMedId": 24837299,
                    "title": "Preclinical antitumor activity of S-222611, an oral reversible tyrosine kinase inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24837299"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2844,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Deguelin inhibited growth of the AGS gastric cancer cell line, which has been reported to harbor PIK3CA and KRAS mutations, in culture (PMID: 20811676, PMID: 24978597).",
            "molecularProfile": {
                "id": 1630,
                "profileName": "KRAS mut PIK3CA mut"
            },
            "therapy": {
                "id": 1867,
                "therapyName": "Deguelin",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 962,
                    "pubMedId": 24978597,
                    "title": "Discovery of novel AKT inhibitors with enhanced anti-tumor effects in combination with the MEK inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24978597"
                },
                {
                    "id": 3500,
                    "pubMedId": 20811676,
                    "title": "Deguelin promotes apoptosis and inhibits angiogenesis of gastric cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20811676"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2846,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, S-222611 resulted in a complete response in a gastric-esophageal junction cancer patient overexpressing ERBB2 (HER2) and a partial response in a gastric cancer patient also overexpressing ERBB2 (HER2) (J Clin Oncol 33, 2015 (suppl; abstr 2511)).",
            "molecularProfile": {
                "id": 1270,
                "profileName": "ERBB2 over exp"
            },
            "therapy": {
                "id": 1048,
                "therapyName": "S-222611",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3502,
                    "pubMedId": null,
                    "title": "Phase I expansion of S-222611, a reversible inhibitor of EGFR and HER2, in advanced solid tumors, including patients with brain metastases",
                    "url": "http://meetinglibrary.asco.org/content/148414-156"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2852,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Varlitinib (ARRY-334543), in combination with Herceptin (trastuzumab), resulted in a 91% tumor growth inhibition and tumor regression in human cell line xenograft models of gastric cancer overexpressing ERBB2 (HER2) (Cancer Res January 15, 2009 69; 2150).",
            "molecularProfile": {
                "id": 1270,
                "profileName": "ERBB2 over exp"
            },
            "therapy": {
                "id": 3034,
                "therapyName": "Trastuzumab + Varlitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3506,
                    "pubMedId": null,
                    "title": "In vivo activity of ARRY-543, a potent, small molecule inhibitor of EGFR/ErbB-2 in combination with trastuzumab or docetaxel",
                    "url": "http://cancerres.aacrjournals.org/content/69/2_Supplement/2150"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2860,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD5363 inhibited proliferation of the AGS gastric cancer cell line, which has been reported to harbor KRAS G12D and PIK3CA E453K mutations (PMID: 24088382, PMID: 19755509).",
            "molecularProfile": {
                "id": 10717,
                "profileName": "KRAS G12D PIK3CA E453K"
            },
            "therapy": {
                "id": 655,
                "therapyName": "Capivasertib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1081,
                    "pubMedId": 24088382,
                    "title": "The AKT inhibitor AZD5363 is selectively active in PI3KCA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to Taxotere.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24088382"
                },
                {
                    "id": 3510,
                    "pubMedId": 19755509,
                    "title": "Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19755509"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2889,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tucatinib (ARRY-380) inhibited proliferation of an ERBB2 (HER2) over expressing gastric cancer cell line in culture (Cancer Res April 15, 2010 70:3610).",
            "molecularProfile": {
                "id": 1270,
                "profileName": "ERBB2 over exp"
            },
            "therapy": {
                "id": 639,
                "therapyName": "Tucatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3515,
                    "pubMedId": null,
                    "title": "Abstract 3610: Pan-ErbB inhibition by ARRY-334543 is superior to selective ErbB inhibition in a preclinical model that signals through multiple ErbB receptors",
                    "url": "http://cancerres.aacrjournals.org/content/70/8_Supplement/3610.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2903,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Varlitinib (ARRY-334543) resulted in a 74% tumor growth inhibition and tumor regression in 88% (7/8) of human cell line xenograft models of gastric cancer overexpressing ERBB2 (HER2) (Cancer Res January 15, 2009 69; 2150).",
            "molecularProfile": {
                "id": 1270,
                "profileName": "ERBB2 over exp"
            },
            "therapy": {
                "id": 1057,
                "therapyName": "Varlitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3506,
                    "pubMedId": null,
                    "title": "In vivo activity of ARRY-543, a potent, small molecule inhibitor of EGFR/ErbB-2 in combination with trastuzumab or docetaxel",
                    "url": "http://cancerres.aacrjournals.org/content/69/2_Supplement/2150"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2905,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TAK-285 inhibited tumor growth in gastric cancer cell line xenograft models over expressing ERBB2 (HER2) (PMID: 23983820).",
            "molecularProfile": {
                "id": 1270,
                "profileName": "ERBB2 over exp"
            },
            "therapy": {
                "id": 2135,
                "therapyName": "TAK-285",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1960,
                    "pubMedId": 23983820,
                    "title": "Antitumor Activity of TAK-285, an Investigational, Non-Pgp Substrate HER2/EGFR Kinase Inhibitor, in Cultured Tumor Cells, Mouse and Rat Xenograft Tumors, and in an HER2-Positive Brain Metastasis Model.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23983820"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2977,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the N87 gastric cancer cell line, which has been demonstrated to have ERBB2 (HER2) amplification and over expression, was sensitive to TAK-285, inhibiting phosphorylation of ERBB2 (HER2) and ERBB3 (HER3) (PMID: 25594012, PMID: 18441328).",
            "molecularProfile": {
                "id": 1270,
                "profileName": "ERBB2 over exp"
            },
            "therapy": {
                "id": 2135,
                "therapyName": "TAK-285",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3531,
                    "pubMedId": 18441328,
                    "title": "HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18441328"
                },
                {
                    "id": 3546,
                    "pubMedId": 25594012,
                    "title": "HER2 and HER3 cooperatively regulate cancer cell growth and determine sensitivity to the novel investigational EGFR/HER2 kinase inhibitor TAK-285.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25594012"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2910,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sapitinib (AZD8931), in combination with Platinol (cisplatin) and Adrucil (fluorouracil), demonstrated safety and an additive effect in a primary gastric cancer xenograft model (Cancer Res April 15, 2013 73; 2090).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3036,
                "therapyName": "Cisplatin + Fluorouracil + Sapitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 3520,
                    "pubMedId": null,
                    "title": "Targeting HER family signaling in gastric cancer: The selective and equipotent EGFR, HER2 and HER3 signaling inhibitor, AZD8931, is efficacious in primary models of HER family driven disease",
                    "url": "http://cancerres.aacrjournals.org/content/73/8_Supplement/2090.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 2911,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tykerb (lapatinib) inhibited growth of HER2-amplified and HER2-over expressing gastric cancer cell lines in culture (PMID: 18774637).",
            "molecularProfile": {
                "id": 1270,
                "profileName": "ERBB2 over exp"
            },
            "therapy": {
                "id": 787,
                "therapyName": "Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3521,
                    "pubMedId": 18774637,
                    "title": "The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18774637"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2913,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gilotrif (afatinib) induced tumor regression in a gastric cancer cell line xenograft model with HER2 (ERBB2) amplification and over expression (PMID: 23578997).",
            "molecularProfile": {
                "id": 25933,
                "profileName": "ERBB2 amp ERBB2 over exp"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3522,
                    "pubMedId": 23578997,
                    "title": "Monitoring afatinib treatment in HER2-positive gastric cancer with 18F-FDG and 89Zr-trastuzumab PET.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23578997"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2917,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Vizimpro (dacomitinib) resulted in a 7.4% (2/27) response rate and 40.7% (11/27) disease control rate when treating advanced gastric cancer patients with ERBB2 (HER2) over expression (J Clin Oncol 30, 2012 (suppl 4; abstr 54)).",
            "molecularProfile": {
                "id": 1270,
                "profileName": "ERBB2 over exp"
            },
            "therapy": {
                "id": 714,
                "therapyName": "Dacomitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3526,
                    "pubMedId": null,
                    "title": "A phase II open-label trial of dacomitinib monotherapy in patients with HER2-positive advanced gastric cancer after failure of at least one prior chemotherapy regimen",
                    "url": "http://meetinglibrary.asco.org/content/88180-115"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 2934,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ERBB2 (HER2) over expressing gastric cancer cells were sensitive to Vizimpro (dacomitinib), resulting in inhibition of ERBB2 (HER2)/ERBB3 (HER3) heterodimers (PMID: 22135232).",
            "molecularProfile": {
                "id": 1270,
                "profileName": "ERBB2 over exp"
            },
            "therapy": {
                "id": 714,
                "therapyName": "Dacomitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3539,
                    "pubMedId": 22135232,
                    "title": "Evaluation of the antitumor effects and mechanisms of PF00299804, a pan-HER inhibitor, alone or in combination with chemotherapy or targeted agents in gastric cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22135232"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2918,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Poziotinib suppressed cell growth, decreased phosphorylation of downstream signaling molecules, and induced apoptosis of human gastric cancer cells harboring ERBB2 (HER2) amplification (PMID: 21306821).",
            "molecularProfile": {
                "id": 531,
                "profileName": "ERBB2 amp"
            },
            "therapy": {
                "id": 1042,
                "therapyName": "Poziotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2314,
                    "pubMedId": 21306821,
                    "title": "Antitumor activity of HM781-36B, an irreversible Pan-HER inhibitor, alone or in combination with cytotoxic chemotherapeutic agents in gastric cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21306821"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2919,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BMS-690514 inhibited tumor growth in a gastric cancer xenograft model with ERBB2 (HER2) amplification and overexpression (PMID: 21531814).",
            "molecularProfile": {
                "id": 531,
                "profileName": "ERBB2 amp"
            },
            "therapy": {
                "id": 685,
                "therapyName": "BMS-690514",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1825,
                    "pubMedId": 21531814,
                    "title": "Antitumor and antiangiogenic activities of BMS-690514, an inhibitor of human EGF and VEGF receptor kinase families.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21531814"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2920,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BMS-690514 inhibited tumor growth in a gastric cancer xenograft model with ERBB2 (HER2) amplification and overexpression (PMID: 21531814).",
            "molecularProfile": {
                "id": 1270,
                "profileName": "ERBB2 over exp"
            },
            "therapy": {
                "id": 685,
                "therapyName": "BMS-690514",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1825,
                    "pubMedId": 21531814,
                    "title": "Antitumor and antiangiogenic activities of BMS-690514, an inhibitor of human EGF and VEGF receptor kinase families.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21531814"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2925,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MM-111, in combination with Herceptin (trastuzumab) and Taxol (paclitaxel), resulted in a synergistic effect thereby inhibiting ErbB2 in ERBB2 (HER2) over expressing gastric cancer cell line xenograft models (J Clin Oncol 31, 2013 (suppl 4; abstr 48)).",
            "molecularProfile": {
                "id": 1270,
                "profileName": "ERBB2 over exp"
            },
            "therapy": {
                "id": 1892,
                "therapyName": "MM-111 + Paclitaxel + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3530,
                    "pubMedId": null,
                    "title": "Preclinical activity of MM-111, a bispecific ErbB2/ErbB3 antibody in previously treated ErbB2-positive gastric and gastroesophageal junction cancer",
                    "url": "http://meetinglibrary.asco.org/content/106018-133"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2926,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CDX-3379 (KTN3379) inhibited tumor growth by 43% in N87 gastric cancer xenograft model, which has been demonstrated to have ERBB2 (HER2) amplification and overexpression (AACR; 2015. Abstract nr 1558, PMID: 18441328).",
            "molecularProfile": {
                "id": 1270,
                "profileName": "ERBB2 over exp"
            },
            "therapy": {
                "id": 2054,
                "therapyName": "CDX-3379",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3531,
                    "pubMedId": 18441328,
                    "title": "HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18441328"
                },
                {
                    "id": 3532,
                    "pubMedId": null,
                    "title": "Association of ErbB/HER biomarkers with antitumor activity of the anti-ErbB3/HER3 monoclonal antibody KTN3379 in SCCHN",
                    "url": "http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=3682&sKey=8ef53702-fa4b-4bcd-959a-adc80c411249&cKey=8eef59f4-1b14-46a5-933b-b20bbb91a185&mKey=19573a54-ae8f-4e00-9c23-bd6d62268424"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2927,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Kadcyla (trastuzumab emtansine) inhibited tumor growth in human cell line xenograft models of gastric cancer with ERBB2 (HER2) amplification and over expression (PMID: 21458915).",
            "molecularProfile": {
                "id": 1270,
                "profileName": "ERBB2 over exp"
            },
            "therapy": {
                "id": 1402,
                "therapyName": "Ado-trastuzumab emtansine",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3533,
                    "pubMedId": 21458915,
                    "title": "Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21458915"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2928,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Kadcyla (trastuzumab emtansine) inhibited tumor growth in human cell line xenograft models of gastric cancer with ERBB2 (HER2) amplification and over expression (PMID: 21458915).",
            "molecularProfile": {
                "id": 25933,
                "profileName": "ERBB2 amp ERBB2 over exp"
            },
            "therapy": {
                "id": 1402,
                "therapyName": "Ado-trastuzumab emtansine",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3533,
                    "pubMedId": 21458915,
                    "title": "Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21458915"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2929,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ERBB2 (HER2) over expressing gastric cancer xenograft models demonstrated anti-tumor activity when treated with MM-302 (Cancer Res December 15, 2010 70; P3-14-09).",
            "molecularProfile": {
                "id": 1270,
                "profileName": "ERBB2 over exp"
            },
            "therapy": {
                "id": 1401,
                "therapyName": "MM-302",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 3534,
                    "pubMedId": null,
                    "title": "Abstract P3-14-09: Preclinical Safety and Activity of MM-302, a HER2-Targeted Liposomal Doxorubicin Designed To Have an Improved Safety and Efficacy Profile over Approved Anthracyclines",
                    "url": "http://cancerres.aacrjournals.org/content/70/24_Supplement/P3-14-09"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2971,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CH5132799 induced tumor regression in xenograft models of a human stomach cancer cell line with deletion of PTEN (PMID: 21558396).",
            "molecularProfile": {
                "id": 2408,
                "profileName": "PTEN del"
            },
            "therapy": {
                "id": 2152,
                "therapyName": "CH5132799",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1985,
                    "pubMedId": 21558396,
                    "title": "The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21558396"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3163,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Herceptin (trastuzumab) inhibited tumor growth in human cell line xenograft models of gastric cancer with ERBB2 (HER2) amplification (PMID: 26296355).",
            "molecularProfile": {
                "id": 531,
                "profileName": "ERBB2 amp"
            },
            "therapy": {
                "id": 947,
                "therapyName": "Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3655,
                    "pubMedId": 26296355,
                    "title": "Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26296355"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3166,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Herceptin (trastuzumab) and Tykerb (lapatinib) treatment induced tumor regression in ERBB2 (HER2)-amplified cell line xenograft models of gastric cancer (PMID: 26296355).",
            "molecularProfile": {
                "id": 531,
                "profileName": "ERBB2 amp"
            },
            "therapy": {
                "id": 1414,
                "therapyName": "Lapatinib + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3655,
                    "pubMedId": 26296355,
                    "title": "Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26296355"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3180,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ERBB3 (HER3) knock-down increased sensitivity of gastric cancer cell lines harboring ERBB2 (HER2) amplification to growth inhibition by Tykerb (lapatinib) in culture (PMID: 26296355).",
            "molecularProfile": {
                "id": 12427,
                "profileName": "ERBB2 amp ERBB3 dec exp"
            },
            "therapy": {
                "id": 787,
                "therapyName": "Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3655,
                    "pubMedId": 26296355,
                    "title": "Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26296355"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3520,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, gastric cancer cells with wild-type FGFR2 were resistant to growth inhibition by Iclusig (ponatinib) in cell culture (PMID: 22238366).",
            "molecularProfile": {
                "id": 543,
                "profileName": "FGFR2 wild-type"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 311,
                    "pubMedId": 22238366,
                    "title": "Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22238366"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3521,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iclusig (ponatinib) inhibited proliferation of FGFR2-amplified gastric cancer cells in culture, and inhibited tumor growth in FGFR2-amplified gastric cancer cell line xenograft models (PMID: 22238366).",
            "molecularProfile": {
                "id": 3147,
                "profileName": "FGFR2 amp"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 311,
                    "pubMedId": 22238366,
                    "title": "Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22238366"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3522,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Dovitinib (TKI258) inhibited cell proliferation in gastric cancer cell lines harboring FGFR2 amplification in culture (PMID: 22238366).",
            "molecularProfile": {
                "id": 3147,
                "profileName": "FGFR2 amp"
            },
            "therapy": {
                "id": 721,
                "therapyName": "Dovitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 311,
                    "pubMedId": 22238366,
                    "title": "Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22238366"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21008,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Cediranib (AZD-2171) inhibited growth of a gastric cancer cell line harboring FGFR2 amplification in culture (PMID: 30045926).",
            "molecularProfile": {
                "id": 3147,
                "profileName": "FGFR2 amp"
            },
            "therapy": {
                "id": 1001,
                "therapyName": "Cediranib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18258,
                    "pubMedId": 30045926,
                    "title": "Acquired JHDM1D-BRAF Fusion Confers Resistance to FGFR Inhibition in FGFR2-Amplified Gastric Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30045926"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3523,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Cediranib (AZD-2171) inhibited growth of gastric cancer cells harboring FGFR2 amplification in culture (PMID: 22238366).",
            "molecularProfile": {
                "id": 3147,
                "profileName": "FGFR2 amp"
            },
            "therapy": {
                "id": 1001,
                "therapyName": "Cediranib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 311,
                    "pubMedId": 22238366,
                    "title": "Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22238366"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3525,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Brivanib (BMS-540215) did not inhibit growth of gastric cancer cells harboring FGFR2 amplification in culture (PMID: 22238366).",
            "molecularProfile": {
                "id": 3147,
                "profileName": "FGFR2 amp"
            },
            "therapy": {
                "id": 996,
                "therapyName": "Brivanib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 311,
                    "pubMedId": 22238366,
                    "title": "Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22238366"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3566,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KU004 inhibited growth and induced apoptosis in gastric cancer cell lines over expressing ERBB2 in culture and suppressed growth in a dose dependent manner in xenograft models (PMID: 26437915).",
            "molecularProfile": {
                "id": 1270,
                "profileName": "ERBB2 over exp"
            },
            "therapy": {
                "id": 3157,
                "therapyName": "KU004",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3826,
                    "pubMedId": 26437915,
                    "title": "A novel dual EGFR/HER2 inhibitor KU004 induces cell cycle arrest and apoptosis in HER2-overexpressing cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26437915"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3819,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Diagnostic",
            "efficacyEvidence": "Pathogenic germline CDH1 mutations are used in the diagnosis of hereditary diffuse gastric cancer (PMID: 26380059, PMID: 26182300).",
            "molecularProfile": {
                "id": 16466,
                "profileName": "CDH1 mutant"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4197,
                    "pubMedId": 26182300,
                    "title": "Hereditary Diffuse Gastric Cancer Syndrome: CDH1 Mutations and Beyond.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26182300"
                },
                {
                    "id": 5723,
                    "pubMedId": 26380059,
                    "title": "Hereditary diffuse gastric cancer: What the clinician should know.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26380059"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 13679,
            "approvalStatus": "Guideline",
            "evidenceType": "Risk Factor",
            "efficacyEvidence": "Germline truncating mutations in CDH1 are associated with hereditary diffuse gastric cancer, which is characterized by increased risk of developing gastric cancer (NCCN.org).",
            "molecularProfile": {
                "id": 16466,
                "profileName": "CDH1 mutant"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 3937,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TAE226 treatment inhibited proliferation of gastric cancer cell lines harboring MET amplification in culture (PMID: 26090892).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 2086,
                "therapyName": "TAE226",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4301,
                    "pubMedId": 26090892,
                    "title": "TAE226, a Bis-Anilino Pyrimidine Compound, Inhibits the EGFR-Mutant Kinase Including T790M Mutant to Show Anti-Tumor Effect on EGFR-Mutant Non-Small Cell Lung Cancer Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26090892"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4022,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, FIIN-01 inhibited Fgfr2-dependent cell proliferation of gastric cancer cell lines harboring FGFR2 amplification (PMID: 20338520).",
            "molecularProfile": {
                "id": 3147,
                "profileName": "FGFR2 amp"
            },
            "therapy": {
                "id": 2507,
                "therapyName": "FIIN-1",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2410,
                    "pubMedId": 20338520,
                    "title": "A structure-guided approach to creating covalent FGFR inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20338520"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4032,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD-6244) did not inhibit growth of gastric cancer cells with FGFR2 amplification in culture (PMID: 19755509).",
            "molecularProfile": {
                "id": 3147,
                "profileName": "FGFR2 amp"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3510,
                    "pubMedId": 19755509,
                    "title": "Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19755509"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7570,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, FGFR2-amplified gastric cancer cell lines demonstrated sensitivity to PD173074 in culture, with cell lines with high-level FGFR2 amplification displaying higher sensitivity compared to cell lines with low-level amplification (PMID: 27179038).",
            "molecularProfile": {
                "id": 3147,
                "profileName": "FGFR2 amp"
            },
            "therapy": {
                "id": 2948,
                "therapyName": "PD173074",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6434,
                    "pubMedId": 27179038,
                    "title": "High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27179038"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4043,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PD173074 inhibited proliferation of a gastric cancer cell line harboring FGFR2 amplification in culture (PMID: 26036639).",
            "molecularProfile": {
                "id": 3147,
                "profileName": "FGFR2 amp"
            },
            "therapy": {
                "id": 2948,
                "therapyName": "PD173074",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4383,
                    "pubMedId": 26036639,
                    "title": "FGFR2 is overexpressed in myxoid liposarcoma and inhibition of FGFR signaling impairs tumor growth in vitro.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26036639"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21007,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PD173074 inhibited growth of a gastric cancer cell line harboring FGFR2 amplification in culture (PMID: 30045926).",
            "molecularProfile": {
                "id": 3147,
                "profileName": "FGFR2 amp"
            },
            "therapy": {
                "id": 2948,
                "therapyName": "PD173074",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18258,
                    "pubMedId": 30045926,
                    "title": "Acquired JHDM1D-BRAF Fusion Confers Resistance to FGFR Inhibition in FGFR2-Amplified Gastric Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30045926"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21004,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BGJ398 inhibited growth of a gastric cancer cell line harboring FGFR2 amplification in culture (PMID: 30045926).",
            "molecularProfile": {
                "id": 3147,
                "profileName": "FGFR2 amp"
            },
            "therapy": {
                "id": 674,
                "therapyName": "BGJ398",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18258,
                    "pubMedId": 30045926,
                    "title": "Acquired JHDM1D-BRAF Fusion Confers Resistance to FGFR Inhibition in FGFR2-Amplified Gastric Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30045926"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4045,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BGJ398 inhibited proliferation of gastric cancer cell lines harboring FGFR2 amplification in culture (PMID: 26036639).",
            "molecularProfile": {
                "id": 3147,
                "profileName": "FGFR2 amp"
            },
            "therapy": {
                "id": 674,
                "therapyName": "BGJ398",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4383,
                    "pubMedId": 26036639,
                    "title": "FGFR2 is overexpressed in myxoid liposarcoma and inhibition of FGFR signaling impairs tumor growth in vitro.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26036639"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4053,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Debio 1347 inhibited proliferation of FGFR-amplified gastric cancer cells in culture and inhibited tumor growth in cell line xenograft models of gastric cancer harboring FGFR2 amplification (PMID: 25169980).",
            "molecularProfile": {
                "id": 3147,
                "profileName": "FGFR2 amp"
            },
            "therapy": {
                "id": 1014,
                "therapyName": "Debio 1347",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4388,
                    "pubMedId": 25169980,
                    "title": "The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25169980"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4082,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a human gastric cancer cell line with high levels of MET expression and expressing KRAS G12D was resistant to Xalkori (crizotinib) mediated growth inhibition in culture (PMID: 26432108).",
            "molecularProfile": {
                "id": 17217,
                "profileName": "KRAS G12D MET over exp"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4397,
                    "pubMedId": 26432108,
                    "title": "Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26432108"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4083,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Xalkori (crizotinib) inhibited growth of a human gastric cancer cell line with high levels of MET expression in culture (PMID: 26432108).",
            "molecularProfile": {
                "id": 5392,
                "profileName": "MET over exp"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4397,
                    "pubMedId": 26432108,
                    "title": "Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26432108"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4391,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BEZ235 demonstrated efficacy in promoting apoptosis of gastric cancer cells harboring a PIK3CA mutation in culture (PMID: 22543857).",
            "molecularProfile": {
                "id": 429,
                "profileName": "PIK3CA mutant"
            },
            "therapy": {
                "id": 672,
                "therapyName": "BEZ235",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 361,
                    "pubMedId": 22543857,
                    "title": "Selective PI3K inhibition by BKM120 and BEZ235 alone or in combination with chemotherapy in wild-type and mutated human gastrointestinal cancer cell lines.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22543857"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4627,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PRN1109 treatment resulted in tumor regression in gastric cancer cell line xenograft models harboring FGFR2 amplification (Eu J Cancer 2014 Vol 50, Suppl 6:157).",
            "molecularProfile": {
                "id": 3147,
                "profileName": "FGFR2 amp"
            },
            "therapy": {
                "id": 4645,
                "therapyName": "PRN1109",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4638,
                    "pubMedId": null,
                    "title": "Irreversible Covalent Pan-FGFR Inhibitors are Highly Efficacious Against FGFR-dependent Cancers",
                    "url": "http://www.ejcancer.com/article/S0959-8049%2814%2970609-4/pdf"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4894,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, gastric cancer cells with PIM1 overexpression demonstrated sensitivity to K00135 in culture, resulting in reduced cell survival (PMID: 21993851).",
            "molecularProfile": {
                "id": 14615,
                "profileName": "PIM1 over exp"
            },
            "therapy": {
                "id": 3674,
                "therapyName": "K00135",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4427,
                    "pubMedId": 21993851,
                    "title": "Clinical and therapeutic relevance of PIM1 kinase in gastric cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21993851"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5026,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Vismodegib (GDC-0449) inhibited Hedgehog pathway signaling, increased apoptosis, and decreased proliferation of a gastric cancer cell line in culture (PMID: 26676867).",
            "molecularProfile": {
                "id": 691,
                "profileName": "SMO wild-type"
            },
            "therapy": {
                "id": 956,
                "therapyName": "Vismodegib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4842,
                    "pubMedId": 26676867,
                    "title": "Reduced proliferation and increased apoptosis of the SGC\u20117901 gastric cancer cell line on exposure to GDC\u20110449.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26676867"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5062,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, gastric cancer cells harboring POLB L259S demonstrated resistance to Platinol (cisplatin), resulting in increased cell survival (PMID: 25561897).",
            "molecularProfile": {
                "id": 20229,
                "profileName": "POLB L259S"
            },
            "therapy": {
                "id": 700,
                "therapyName": "Cisplatin",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4869,
                    "pubMedId": 25561897,
                    "title": "Clinical significance of a point mutation in DNA polymerase beta (POLB) gene in gastric cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25561897"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5397,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, OPB-31121 inhibited cell proliferation of Stat3-positive gastric cancer cells in culture and suppressed tumor growth in cell line xenograft models (PMID: 23402820).",
            "molecularProfile": {
                "id": 20856,
                "profileName": "STAT3 positive"
            },
            "therapy": {
                "id": 3852,
                "therapyName": "OPB-31121",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5045,
                    "pubMedId": 23402820,
                    "title": "OPB-31121, a novel small molecular inhibitor, disrupts the JAK2/STAT3 pathway and exhibits an antitumor activity in gastric cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23402820"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5400,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Adrucil (fluorouracil) and OPB-31121 worked synergistically to inhibit growth of Stat3-positive gastric cancer cells sensitive or resistant to OPB-31121 in culture (PMID: 23402820).",
            "molecularProfile": {
                "id": 20856,
                "profileName": "STAT3 positive"
            },
            "therapy": {
                "id": 3859,
                "therapyName": "Fluorouracil + OPB-31121",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5045,
                    "pubMedId": 23402820,
                    "title": "OPB-31121, a novel small molecular inhibitor, disrupts the JAK2/STAT3 pathway and exhibits an antitumor activity in gastric cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23402820"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5401,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Platinol (cisplatin) and OPB-31121 worked synergistically to inhibit growth of Stat3-positive gastric cancer cells in culture (PMID: 23402820).",
            "molecularProfile": {
                "id": 20856,
                "profileName": "STAT3 positive"
            },
            "therapy": {
                "id": 3860,
                "therapyName": "Cisplatin + OPB-31121",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5045,
                    "pubMedId": 23402820,
                    "title": "OPB-31121, a novel small molecular inhibitor, disrupts the JAK2/STAT3 pathway and exhibits an antitumor activity in gastric cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23402820"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5498,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KRC-00715 induced cell-cycle arrest and inhibited growth of Met-over expressing gastric cancer cell lines in culture and in xenograft models, and did not inhibit growth of cell lines with low Met expression (PMID: 26801760).",
            "molecularProfile": {
                "id": 5392,
                "profileName": "MET over exp"
            },
            "therapy": {
                "id": 3871,
                "therapyName": "KRC-00715",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5073,
                    "pubMedId": 26801760,
                    "title": "Novel c-Met inhibitor suppresses the growth of c-Met-addicted gastric cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26801760"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5500,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KRC-00509 induced cell-cycle arrest and inhibited growth of Met-over expressing gastric cancer cell lines in culture, and did not inhibit growth of cell lines with low Met expression (PMID: 26801760).",
            "molecularProfile": {
                "id": 5392,
                "profileName": "MET over exp"
            },
            "therapy": {
                "id": 3872,
                "therapyName": "KRC-00509",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5073,
                    "pubMedId": 26801760,
                    "title": "Novel c-Met inhibitor suppresses the growth of c-Met-addicted gastric cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26801760"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5898,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MET amplified gastric cancer cell lines were sensitive to TAS-115, resulting in suppression of cell proliferation in culture (PMID: 24140932).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 3976,
                "therapyName": "TAS-115",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5188,
                    "pubMedId": 24140932,
                    "title": "The novel VEGF receptor/MET-targeted kinase inhibitor TAS-115 has marked in vivo antitumor properties and a favorable tolerability profile.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24140932"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6054,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, HD105 inhibited tumor progression in two of four human gastric cancer cell line xenograft models (PMID: 27049350).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4011,
                "therapyName": "HD105",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5258,
                    "pubMedId": 27049350,
                    "title": "Simultaneous blockade of VEGF and Dll4 by HD105, a bispecific antibody, inhibits tumor progression and angiogenesis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27049350"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6060,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AT13148 inhibited proliferation and induced apoptosis in gastric cancer cell lines in culture and inhibited tumor growth in a gastric cancer cell line xenograft model (PMID: 26828267).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3653,
                "therapyName": "AT13148",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5268,
                    "pubMedId": 26828267,
                    "title": "AT13148, a first-in-class multi-AGC kinase inhibitor, potently inhibits\u00a0gastric cancer cells both in\u00a0vitro and in\u00a0vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26828267"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6422,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Geldanamycin inhibited proliferation of a human gastric cancer cell line in culture (PMID: 26788199).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4092,
                "therapyName": "Geldanamycin",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5575,
                    "pubMedId": 26788199,
                    "title": "Geldanamycin induces apoptosis in human gastric carcinomas by affecting multiple oncogenic kinases that have synergic effects with TNF-related apoptosis-inducing ligand.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26788199"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6427,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, gastric cancer cell lines with decreased Cblb expression level via shRNA knockdown demonstrated reduced sensitivity to Adrucil (fluorouracil) in cell culture (PMID: 24351824).",
            "molecularProfile": {
                "id": 23411,
                "profileName": "CBLB dec exp"
            },
            "therapy": {
                "id": 1715,
                "therapyName": "Fluorouracil",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 5588,
                    "pubMedId": 24351824,
                    "title": "Cbl-b enhances sensitivity to 5-fluorouracil via EGFR- and mitochondria-mediated pathways in gastric cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24351824"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6456,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CDX-3379 (KTN3379) had minor inhibitory effect on tumor growth in xenograft models of gastric cancer expressing high levels of Erbb3 (Her3) and low levels of Nrg1 (Hrg) (PMID: 26880266).",
            "molecularProfile": {
                "id": 23518,
                "profileName": "ERBB3 over exp NRG1 dec exp"
            },
            "therapy": {
                "id": 2054,
                "therapyName": "CDX-3379",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5601,
                    "pubMedId": 26880266,
                    "title": "A Potent HER3 Monoclonal Antibody That Blocks Both Ligand-Dependent and -Independent Activities: Differential Impacts of PTEN Status on Tumor Response.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26880266"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6461,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Erbitux (cetuximab) and CDX-3379 (KTN3379) synergized to inhibit tumor growth in human cell line xenograft models of gastric cancer expressing Erbb3 (Her3) and Nrg1 (Hrg) (PMID: 26880266).",
            "molecularProfile": {
                "id": 23514,
                "profileName": "ERBB3 pos NRG1 pos"
            },
            "therapy": {
                "id": 2061,
                "therapyName": "CDX-3379 + Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5601,
                    "pubMedId": 26880266,
                    "title": "A Potent HER3 Monoclonal Antibody That Blocks Both Ligand-Dependent and -Independent Activities: Differential Impacts of PTEN Status on Tumor Response.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26880266"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6492,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a gastric cancer cell line harboring MAP2K1 Q56P demonstrated sensitivity to Mekinist (trametinib), resulting in decreased cell viability (PMID: 26582713).",
            "molecularProfile": {
                "id": 584,
                "profileName": "MAP2K1 Q56P"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5602,
                    "pubMedId": 26582713,
                    "title": "Identification of an \"Exceptional Responder\" Cell Line to MEK1 Inhibition: Clinical Implications for MEK-Targeted Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26582713"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7136,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LY3039478 inhibited Notch1 cleavage and downstream gene expression, demonstrated anti-tumor activity in xenograft models of gastric cancer (AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 1131).",
            "molecularProfile": {
                "id": 5943,
                "profileName": "NOTCH1 positive"
            },
            "therapy": {
                "id": 2958,
                "therapyName": "LY3039478",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3325,
                    "pubMedId": null,
                    "title": "Abstract 1131: Novel inhibitor of Notch signaling for the treatment of cancer.",
                    "url": "http://cancerres.aacrjournals.org/content/73/8_Supplement/1131.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7604,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, M-COPA reduced Met cell surface expression and downstream signaling and decreased growth of MET-amplified gastric cancer cell lines in culture, and demonstrated antitumor activity in MET-amplified gastric cancer cell line xenograft models (PMID: 27197184).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 4522,
                "therapyName": "M-COPA",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6440,
                    "pubMedId": 27197184,
                    "title": "M-COPA, a Golgi Disruptor, Inhibits Cell Surface Expression of MET Protein and Exhibits Antitumor Activity against MET-Addicted Gastric Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27197184"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7764,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LY3164530 demonstrated anti-tumor activity in cell line xenograft models of gastric cancer (AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 873).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1969,
                "therapyName": "LY3164530",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6485,
                    "pubMedId": null,
                    "title": "A novel MET-EGFR bispecific antibody LY3164530 shows advantage over combining MET and EGFR antibodies in tumor inhibition and overcome resistance",
                    "url": "http://cancerres.aacrjournals.org/content/76/14_Supplement/873"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8154,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Tykerb (lapatinib) and Xeloda (capecitabine) combination treatment resulted in partial response in 17.9% (12/67) and stable disease in 46.3% (31/67) of gastric cancer patients regardless of their ERBB2 (HER2) status, although increased Erbb3 (Her3) expression level correlated with higher response rate (PMID: 27325685).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1399,
                "therapyName": "Capecitabine + Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6561,
                    "pubMedId": 27325685,
                    "title": "A Phase II Biomarker-Embedded Study of Lapatinib plus Capecitabine as First-line Therapy in Patients with Advanced or Metastatic Gastric Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27325685"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8281,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Apatinib (YN968D1) inhibited tumor growth in gastric cancer cell line xenograft models (PMID: 21443688).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 986,
                "therapyName": "Apatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 592,
                    "pubMedId": 21443688,
                    "title": "YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21443688"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8422,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, knockdown of ATM in a gastric cancer cell line resulted in increased sensitivity to Veliparib (ABT-888) in culture and in xenograft models (PMID: 27638859).",
            "molecularProfile": {
                "id": 1391,
                "profileName": "ATM dec exp"
            },
            "therapy": {
                "id": 954,
                "therapyName": "Veliparib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6647,
                    "pubMedId": 27638859,
                    "title": "ATM Expression Predicts Veliparib and Irinotecan Sensitivity in Gastric Cancer by Mediating P53-Independent Regulation of Cell Cycle and Apoptosis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27638859"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8495,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Debio 1347 did not inhibit tumor growth in cell line xenograft models of MET amplified gastric cancer (PMID: 26438159).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 1014,
                "therapyName": "Debio 1347",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 4382,
                    "pubMedId": 26438159,
                    "title": "ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26438159"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8708,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KTN0073-IgG2 inhibited MET phosphorylation and induced MET degradation, and inhibited growth of a MET-amplified gastric cancer cell line in culture and in xenograft models (PMID: 27550450).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 4799,
                "therapyName": "KTN0073-IgG2",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6713,
                    "pubMedId": 27550450,
                    "title": "Antitumor Properties of an IgG2-Enhanced Next-Generation MET Monoclonal Antibody That Degrades Wild-Type and Mutant MET Receptors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27550450"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8742,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, addition of Erbitux (cetuximab) to chemotherapy consisted of capecitabine and cisplatin did not improve progression free survival over chemotherapy alone (4.4 vs 5.6 months) in patients with advanced gastric cancer (PMID: 23594786).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6727,
                    "pubMedId": 23594786,
                    "title": "Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23594786"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 8743,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, Afinitor (everolimus) did not significantly improve overall survival (5.4 vs 4.3 months) and progression free survival (1.7 vs 1.4 months) over placebo in previously treated advanced gastric cancer patients (PMID: 24043745).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 735,
                "therapyName": "Everolimus",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6728,
                    "pubMedId": 24043745,
                    "title": "Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24043745"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 8749,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, addition of Avastin (bevacizumab) to chemotherapy consisted of fluoropyrimidine and cisplatin resulted in improved median overall survival (12.1 vs 10.1 months), median progression-free survival (6.7 vs 5.3 months) and overall response rate (46.0% vs 37.4%) compared to chemotherapy alone in gastric cancer patients (PMID: 21844504).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 667,
                "therapyName": "Bevacizumab",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6731,
                    "pubMedId": 21844504,
                    "title": "Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21844504"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8759,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, addition of Nimotuzumab to Camptosar (irinotecan) did not significantly improve median progression-free survival (73 vs 85 days), median overall survival (250.5 vs 232.0 days) and response rate (18.4 vs 10.3 %) compared to Camptosar alone in gastric cancer patients (PMID: 25185971).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4806,
                "therapyName": "Irinotecan + Nimotuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6733,
                    "pubMedId": 25185971,
                    "title": "Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25185971"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 8760,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, addition of Nimotuzumab to Camptosar (irinotecan) improved median progression-free survival (118.5 vs 59.0 days), median overall survival (358.5 vs 229.5 days) and response rate (33.3% vs 0.0 %) compared to Camptosar alone in EGFR positive gastric cancer patients (PMID: 25185971).",
            "molecularProfile": {
                "id": 1102,
                "profileName": "EGFR positive"
            },
            "therapy": {
                "id": 4806,
                "therapyName": "Irinotecan + Nimotuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6733,
                    "pubMedId": 25185971,
                    "title": "Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25185971"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 8763,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Stivarga (regorafenib) improved progression free survival compared to placebo in patients with refractory advanced oesophagogastric cancer (J Clin Oncol 33, 2015 (suppl; abstr 4003)).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 890,
                "therapyName": "Regorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6734,
                    "pubMedId": null,
                    "title": "INTEGRATE: A randomized, phase II, double-blind, placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC): A study by the Australasian Gastrointestinal Trials Group (AGITG)\u2014Final overall and subgroup results.",
                    "url": "http://meetinglibrary.asco.org/content/147938-156"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8765,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, addition of Lynparza (olaparib) to Taxol (paclitaxel) did not significantly improve progression free survival (3.91 vs 3.55 months) compared to Taxol alone, but did significantly prolong overall survival (13.1 vs 8.3 months) in patients with metastatic gastric cancer (PMID: 26282658; NCT01063517).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4807,
                "therapyName": "Olaparib + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6735,
                    "pubMedId": 26282658,
                    "title": "Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26282658"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12605,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (GOLD), addition of Lynparza (olaparib) to Taxol (paclitaxel) did not significantly improve overall survival (8.8 vs 6.9 months, HR=0.79, p=0.026) compared to Taxol (paclitaxel) alone in Asian patients with advanced gastric cancer (PMID: 29103871; NCT01924533).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4807,
                "therapyName": "Olaparib + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10476,
                    "pubMedId": 29103871,
                    "title": "Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29103871"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8766,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, addition of Lynparza (olaparib) to Taxol (paclitaxel) did not significantly improve progression free survival (5.29 vs 3.68 months) compared to Taxol alone, but did significantly prolong overall survival (HR = 0.35) in metastatic gastric cancer patients with decreased Atm expression (PMID: 26282658; NCT01063517).",
            "molecularProfile": {
                "id": 1391,
                "profileName": "ATM dec exp"
            },
            "therapy": {
                "id": 4807,
                "therapyName": "Olaparib + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6735,
                    "pubMedId": 26282658,
                    "title": "Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26282658"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 8772,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Yervoy (ipilimumab) did not improve immune-related progression-free survival (2.9 vs 4.9 months) compared to best supportive care in patients with unresectable, locally advanced/metastatic gastric or gastroesophageal junction cancer (J Clin Oncol 34, 2016 (suppl; abstr 4011)).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 779,
                "therapyName": "Ipilimumab",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6738,
                    "pubMedId": null,
                    "title": "A randomized, open-label, two-arm phase II trial comparing the efficacy of sequential ipilimumab (ipi) versus best supportive care (BSC) following first-line (1L) chemotherapy in patients with unresectable, locally advanced/metastatic (A/M) gastric or gas",
                    "url": "http://meetinglibrary.asco.org/content/166431-176"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 8778,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Bavencio (avelumab) treatment resulted in partial response in 27% (3/11) of patients with advanced gastric cancer (J Clin Oncol 33, 2015 (suppl; abstr 4047)).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3144,
                "therapyName": "Avelumab",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6744,
                    "pubMedId": null,
                    "title": "A phase I dose expansion trial of avelumab (MSB0010718C), an anti-PD-L1 antibody, in Japanese patients with advanced gastric cancer.",
                    "url": "http://meetinglibrary.asco.org/content/147815-156"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8779,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I/II trial, Opdivo (nivolumab), alone or incombination with Yervoy (ipilimumab), demonstrated safety and efficacy in patients with chemotherapy-refractory gastric cancer, resulted in a disease control rate of 38% (61/160) (J Clin Oncol 34, 2016 (suppl; abstr 4010)).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1312,
                "therapyName": "Nivolumab",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6745,
                    "pubMedId": null,
                    "title": "CheckMate-032: Phase I/II, open-label study of safety and activity of nivolumab (nivo) alone or with ipilimumab (ipi) in advanced and metastatic (A/M) gastric cancer (GC).",
                    "url": "http://meetinglibrary.asco.org/content/165665-176"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8780,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I/II trial, Opdivo (nivolumab), alone or incombination with Yervoy (ipilimumab), demonstrated safety and efficacy in patients with chemotherapy-refractory gastric cancer, resulted in a disease control rate of 38% (61/160) (J Clin Oncol 34, 2016 (suppl; abstr 4010)).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1627,
                "therapyName": "Ipilimumab + Nivolumab",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6745,
                    "pubMedId": null,
                    "title": "CheckMate-032: Phase I/II, open-label study of safety and activity of nivolumab (nivo) alone or with ipilimumab (ipi) in advanced and metastatic (A/M) gastric cancer (GC).",
                    "url": "http://meetinglibrary.asco.org/content/165665-176"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8870,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Enhertu (fam-trastuzumab deruxtecan-nxki) inhibited growth of a ERBB2 (HER2)-positive gastric carcinoma cell line in culture and in xenograft models, and induced tumor regression in a patient-derived xenograft (PDX) model of ERBB2 (HER2)-positive gastric cancer (PMID: 27026201).",
            "molecularProfile": {
                "id": 1187,
                "profileName": "ERBB2 positive"
            },
            "therapy": {
                "id": 4844,
                "therapyName": "Fam-trastuzumab deruxtecan-nxki",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6780,
                    "pubMedId": 27026201,
                    "title": "DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27026201"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9027,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AMG 337 inhibited growth of gastric cancer cell lines in culture, and inhibited growth and induced regression of tumors in MET-amplified gastric cancer cell line xenograft models (PMID: 27196782).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 1064,
                "therapyName": "AMG 337",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6878,
                    "pubMedId": 27196782,
                    "title": "In Vitro and In Vivo Activity of AMG 337, a Potent and Selective MET Kinase Inhibitor, in MET-Dependent Cancer Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27196782"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9075,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, sensitivity to PU-H71 was correlated to presence of the epichaperome, a network of chaperome complexes, in gastric cancer cell lines in culture (PMID: 27706135).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1162,
                "therapyName": "PU-H71",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6895,
                    "pubMedId": 27706135,
                    "title": "The epichaperome is an integrated chaperome network that facilitates tumour survival.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27706135"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9094,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Aprutumab ixadotin (BAY1187982) inhibited survival of gastric cancer cell lines with elevated Fgfr2 expression level in culture, and suppressed tumor growth in cell line or patient-derived xenograft models (PMID: 27543601).",
            "molecularProfile": {
                "id": 9798,
                "profileName": "FGFR2 positive"
            },
            "therapy": {
                "id": 2931,
                "therapyName": "Aprutumab ixadotin",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6911,
                    "pubMedId": 27543601,
                    "title": "Preclinical Efficacy of the Auristatin-Based Antibody-Drug Conjugate BAY 1187982 for the Treatment of FGFR2-Positive Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27543601"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9132,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a gastric cancer cell line harboring FGFR2 amplification demonstrated decreased cell viability in culture and antitumor activity in xenograft models when treated with E7090 (PMID: 27535969).",
            "molecularProfile": {
                "id": 3147,
                "profileName": "FGFR2 amp"
            },
            "therapy": {
                "id": 4911,
                "therapyName": "E7090",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6928,
                    "pubMedId": 27535969,
                    "title": "E7090, a Novel Selective Inhibitor of Fibroblast Growth Factor Receptors, Displays Potent Antitumor Activity and Prolongs Survival in Preclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27535969"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9171,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SGX523 inhibited Met signaling and proliferation of MET amplified gastric cancer cells in culture, resulted in tumor growth inhibition in cell line xenograft models (PMID: 19934279).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 916,
                "therapyName": "SGX523",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6981,
                    "pubMedId": 19934279,
                    "title": "SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19934279"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9536,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LY2801653 blocked tumor growth in a gastric cancer cell line xenograft model over expressing Met (PMID: 23275061).",
            "molecularProfile": {
                "id": 5392,
                "profileName": "MET over exp"
            },
            "therapy": {
                "id": 1030,
                "therapyName": "Merestinib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 331,
                    "pubMedId": 23275061,
                    "title": "LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23275061"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9553,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, high ATM expression was associated with decreased response to Veliparib (ABT-888) in gastric cancer cell lines in culture (PMID: 27638859).",
            "molecularProfile": {
                "id": 26891,
                "profileName": "ATM over exp"
            },
            "therapy": {
                "id": 954,
                "therapyName": "Veliparib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6647,
                    "pubMedId": 27638859,
                    "title": "ATM Expression Predicts Veliparib and Irinotecan Sensitivity in Gastric Cancer by Mediating P53-Independent Regulation of Cell Cycle and Apoptosis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27638859"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9554,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Camptosar (irinotecan) and Veliparib (ABT-888) demonstrated synergy in gastric cancer cell lines with high ATM expression, resulting in increased apoptosis in culture, and enhanced tumor growth inhibition in cell line xenograft models (PMID: 27638859).",
            "molecularProfile": {
                "id": 26891,
                "profileName": "ATM over exp"
            },
            "therapy": {
                "id": 3314,
                "therapyName": "Irinotecan + Veliparib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6647,
                    "pubMedId": 27638859,
                    "title": "ATM Expression Predicts Veliparib and Irinotecan Sensitivity in Gastric Cancer by Mediating P53-Independent Regulation of Cell Cycle and Apoptosis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27638859"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9555,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, high ATM expression was associated with decreased response to Camptosaur (irinotecan) in gastric cancer cell lines in culture (PMID: 27638859).",
            "molecularProfile": {
                "id": 26891,
                "profileName": "ATM over exp"
            },
            "therapy": {
                "id": 1074,
                "therapyName": "Irinotecan",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6647,
                    "pubMedId": 27638859,
                    "title": "ATM Expression Predicts Veliparib and Irinotecan Sensitivity in Gastric Cancer by Mediating P53-Independent Regulation of Cell Cycle and Apoptosis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27638859"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9670,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, gastric cancer cell lines over expressing FGFR3 and FGF9, and resistant to Herceptin (trastuzumab), demonstrated sensitivity to AZD4547 in culture, resulting in decreased cell growth (PMID: 27267856).",
            "molecularProfile": {
                "id": 26963,
                "profileName": "FGF9 over exp FGFR3 over exp"
            },
            "therapy": {
                "id": 654,
                "therapyName": "AZD4547",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7462,
                    "pubMedId": 27267856,
                    "title": "An FGFR3 Autocrine Loop Sustains Acquired Resistance to Trastuzumab in Gastric Cancer Patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27267856"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9671,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Dovitinib (TKI258) resulted in inhibition of cell migration and decreased phosphorylation of Akt in a Herceptin (trastuzumab) resistant gastric cancer cell line over expressing FGFR3 and FGF9 in culture, and decreased tumor volume in xenograft models (PMID: 27267856).",
            "molecularProfile": {
                "id": 26963,
                "profileName": "FGF9 over exp FGFR3 over exp"
            },
            "therapy": {
                "id": 721,
                "therapyName": "Dovitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7462,
                    "pubMedId": 27267856,
                    "title": "An FGFR3 Autocrine Loop Sustains Acquired Resistance to Trastuzumab in Gastric Cancer Patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27267856"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9970,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, a gastric cancer patient harboring MET amplification was sensitive to treatment with ARGX-111, demonstrating stable disease, a metabolic response, and a decrease in circulating tumor cells (Journal of Clinical Oncology 33, no. 15_suppl (May 2015) 2580-2580).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 2157,
                "therapyName": "ARGX-111",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7830,
                    "pubMedId": null,
                    "title": "A phase I, first-in-human study of argx-111, a monoclonal antibody targeting c-met in patients with solid tumors",
                    "url": "http://ascopubs.org/doi/abs/10.1200/jco.2015.33.15_suppl.2580"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9979,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ABBV-399 inhibited growth of MET-amplified gastric cancer cell in culture, and induced tumor regression in a MET-amplified gastric cancer cell line xenograft model (PMID: 27573171).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 1363,
                "therapyName": "Telisotuzumab vedotin",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7833,
                    "pubMedId": 27573171,
                    "title": "ABBV-399, a c-Met Antibody-Drug Conjugate that Targets Both MET-Amplified and c-Met-Overexpressing Tumors, Irrespective of MET Pathway Dependence.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27573171"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10028,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BGJ398 decreased Myc expression and inhibited tumor growth in patient-derived xenograft (PDX) models of gastric cancer with FGFR2 amplification and over expression (PMID: 27401245).",
            "molecularProfile": {
                "id": 27227,
                "profileName": "FGFR2 amp FGFR2 over exp"
            },
            "therapy": {
                "id": 674,
                "therapyName": "BGJ398",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7899,
                    "pubMedId": 27401245,
                    "title": "c-Myc Alteration Determines the Therapeutic Response to FGFR Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27401245"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10029,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD4547 decreased Myc expression and inhibited tumor growth in patient-derived xenograft (PDX) models of gastric cancer with FGFR2 amplification and over expression (PMID: 27401245).",
            "molecularProfile": {
                "id": 27227,
                "profileName": "FGFR2 amp FGFR2 over exp"
            },
            "therapy": {
                "id": 654,
                "therapyName": "AZD4547",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7899,
                    "pubMedId": 27401245,
                    "title": "c-Myc Alteration Determines the Therapeutic Response to FGFR Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27401245"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10067,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Altiratinib (DCC-0701) inhibited Met phosphorylation and proliferation of a gastric cancer cell line with MET amplification and over expression in culture, and inhibited tumor growth and induced tumor regression in xenograft models (PMID: 26285778).",
            "molecularProfile": {
                "id": 1066,
                "profileName": "MET amp MET over exp"
            },
            "therapy": {
                "id": 1656,
                "therapyName": "Altiratinib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7263,
                    "pubMedId": 26285778,
                    "title": "Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26285778"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10117,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MET Y1230H was associated with resistance to PHA-665752 in a gastric cancer cell line with MET over expression in culture (PMID: 21266357).",
            "molecularProfile": {
                "id": 27261,
                "profileName": "MET Y1230H MET over exp"
            },
            "therapy": {
                "id": 2162,
                "therapyName": "PHA-665752",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 8043,
                    "pubMedId": 21266357,
                    "title": "Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21266357"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10118,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, an acquired MET Y1230C mutation was associated with resistance to PHA-665752 in a MET-over expressing gastric cancer cell line xenograft model, and cells derived from this xenograft model demonstrated sustained MET activation following treatment with PHA-665752 in culture (PMID: 21266357).",
            "molecularProfile": {
                "id": 27262,
                "profileName": "MET Y1230C MET over exp"
            },
            "therapy": {
                "id": 2162,
                "therapyName": "PHA-665752",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 8043,
                    "pubMedId": 21266357,
                    "title": "Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21266357"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10119,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, acquired MET Y1230C and MET Y1230H mutations were associated with secondary resistance to Xalkori (crizotinib) in a MET-over expressing gastric cancer cell line xenograft model, and cells derived from this model demonstrated resistance to Xalkori (crizotinib) in culture (PMID: 21266357).",
            "molecularProfile": {
                "id": 27263,
                "profileName": "MET Y1230C MET Y1230H MET over exp"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 8043,
                    "pubMedId": 21266357,
                    "title": "Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21266357"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10317,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Chiauranib (CS2164) inhibited tumor growth in a gastric cancer cell line xenograft model (PMID: 28004478).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1998,
                "therapyName": "Chiauranib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 8299,
                    "pubMedId": 28004478,
                    "title": "CS2164, a novel multi-target inhibitor against tumor angiogenesis, mitosis and chronic inflammation with anti-tumor potency.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28004478"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 10448,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Margetuximab (MGAH22) treatment resulted in partial responses in 12% (7/60) and stable disease in 50% (30/60) of patients with ERBB2 (HER2)-positive breast or gastric cancer, or other carcinomas that overexpress Erbb2 (Her2) (PMID: 28119295).",
            "molecularProfile": {
                "id": 1187,
                "profileName": "ERBB2 positive"
            },
            "therapy": {
                "id": 808,
                "therapyName": "MGAH22",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8461,
                    "pubMedId": 28119295,
                    "title": "First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28119295"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10604,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a gastric cancer cell line with decreased expression of HDAC1 and ATM was sensitive to AZD6738, demonstrating inhibition of cell-cycle progression, apoptosis, and DNA damage accumulation in culture, and decreased tumor volume and increased apoptotic activity in xenograft models (PMID: 28138034).",
            "molecularProfile": {
                "id": 27649,
                "profileName": "ATM dec exp HDAC1 dec exp"
            },
            "therapy": {
                "id": 2881,
                "therapyName": "AZD6738",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8664,
                    "pubMedId": 28138034,
                    "title": "AZD6738, A Novel Oral Inhibitor of ATR, Induces Synthetic Lethality with ATM Deficiency in Gastric Cancer Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28138034"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10605,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of AZD6738 to Taxol (paclitaxel) treatment in a gastric cancer cell line in culture resulted in enhanced chemotherapeutic sensitivity, demonstrating a synergistic effect (PMID: 28138034).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5565,
                "therapyName": "AZD6738 + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 8664,
                    "pubMedId": 28138034,
                    "title": "AZD6738, A Novel Oral Inhibitor of ATR, Induces Synthetic Lethality with ATM Deficiency in Gastric Cancer Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28138034"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 10606,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of AZD6738 to Platinol (cisplatin) treatment in a gastric cancer cell line in culture resulted in enhanced chemotherapeutic sensitivity, demonstrating a synergistic effect (PMID: 28138034).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3876,
                "therapyName": "AZD6738 + Cisplatin",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 8664,
                    "pubMedId": 28138034,
                    "title": "AZD6738, A Novel Oral Inhibitor of ATR, Induces Synthetic Lethality with ATM Deficiency in Gastric Cancer Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28138034"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 10687,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TY-011 inhibited activities of Aurora kinase A and Aurora kinase B, resulting in growth inhibition in culture and decrease tumor size and angiogenesis in cell line xenograft models of gastric cancer (PMID: 27887633).",
            "molecularProfile": {
                "id": 27730,
                "profileName": "AURKA pos AURKB pos"
            },
            "therapy": {
                "id": 5586,
                "therapyName": "TY-011",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8743,
                    "pubMedId": 27887633,
                    "title": "Antitumor activity of TY-011 against gastric cancer by inhibiting Aurora A, Aurora B and VEGFR2 kinases.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27887633"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10756,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Golvatinib (E7050) inhibited Met and Kdr (Vegfr2) phosphorylation, resulted in growth inhibition of gastric cancer cell lines in culture and in cell line xenograft models (PMID: 19832844).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 1019,
                "therapyName": "Golvatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 41,
                    "pubMedId": 19832844,
                    "title": "E7050: a dual c-Met and VEGFR-2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19832844"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10878,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination of MM-302 and Herceptin (trastuzumab) resulted in improved tumor growth inhibition in cell line xenograft models of Erbb2 (Her2)-over expressing gastric cancer (PMID: 26759238).",
            "molecularProfile": {
                "id": 1270,
                "profileName": "ERBB2 over exp"
            },
            "therapy": {
                "id": 1888,
                "therapyName": "MM-302 + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8885,
                    "pubMedId": 26759238,
                    "title": "Dual HER2 Targeting with Trastuzumab and Liposomal-Encapsulated Doxorubicin (MM-302) Demonstrates Synergistic Antitumor Activity in Breast and Gastric Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26759238"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10926,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Adriamycin (doxorubicin) and Tozasertib (VX-680) decreased Survivin expression and worked synergistically to reduce viability of a gastric cancer cell line in culture (PMID: 28218735).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5688,
                "therapyName": "Doxorubicin + Tozasertib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 8937,
                    "pubMedId": 28218735,
                    "title": "Aurora kinase A regulates Survivin stability through targeting FBXL7 in gastric cancer drug resistance and prognosis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28218735"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 10959,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, two gastric cancer patients demonstrated stable disease when treated with OPB-111077 (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr B118).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5739,
                "therapyName": "OPB-111077",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 8960,
                    "pubMedId": null,
                    "title": "Abstract B118: A phase 1, open-label multiple dose escalation trial to determine safety and tolerability of once daily OPB-111077 in subjects with advanced cancer",
                    "url": "http://mct.aacrjournals.org/content/14/12_Supplement_2/B118.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11118,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RXC004 inhibited tumor growth in patient-derived xenograft models of gastric cancer harboring RNF43 loss-of-function mutations (J Clin Oncol 35, 2017 (suppl; abstr e14094)).",
            "molecularProfile": {
                "id": 8767,
                "profileName": "RNF43 inact mut"
            },
            "therapy": {
                "id": 5865,
                "therapyName": "RXC004",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9091,
                    "pubMedId": null,
                    "title": "Novel porcupine (PORCN) inhibitor RXC004: Evaluation in models of RNF43 loss of function cancers.",
                    "url": "http://abstracts.asco.org/199/AbstView_199_193236.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11178,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Balversa (erdafitinib) inhibited proliferation of a gastric cancer cell line with FGFR2 amplification in culture, and inhibited tumor growth in xenograft models (PMID: 28341788).",
            "molecularProfile": {
                "id": 3147,
                "profileName": "FGFR2 amp"
            },
            "therapy": {
                "id": 1028,
                "therapyName": "Erdafitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9140,
                    "pubMedId": 28341788,
                    "title": "Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28341788"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11506,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ERBB2 (HER2)-specific CAR-T cells induced cell death in ERBB2 (HER2)-over expressing gastric cancer cell lines in culture, and inhibited tumor growth and improved survival in a ERBB2 (HER2)-over expressing gastric cancer cell line xenograft model (PMID: 28284008).",
            "molecularProfile": {
                "id": 1270,
                "profileName": "ERBB2 over exp"
            },
            "therapy": {
                "id": 6007,
                "therapyName": "HER2 CAR-T cells",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9588,
                    "pubMedId": 28284008,
                    "title": "Effective and persistent antitumor activity of HER2-directed CAR-T cells against gastric cancer cells in vitro and xenotransplanted tumors in vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28284008"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11622,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, gastric cancer patients treated with LY2874455 demonstrated some efficacy, including one patient with a partial response, 12 patients with stable disease after two cycles, and 4 patients with stable disease after four cycles of treatment, and had a median progression free survival of 62 days (PMID: 28589492).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2032,
                "therapyName": "LY2874455",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9670,
                    "pubMedId": 28589492,
                    "title": "A Phase 1 Study of LY2874455, an Oral Selective pan-FGFR Inhibitor, in Patients with Advanced Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28589492"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11760,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a gastric adenocarcinoma cell line (PMID: 15494073) treated with Capmatinib (INC280) in culture for several months developed resistance and was found to harbor MET Y1230C (PMID: 28765324).",
            "molecularProfile": {
                "id": 26644,
                "profileName": "MET Y1230C"
            },
            "therapy": {
                "id": 1065,
                "therapyName": "Capmatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9757,
                    "pubMedId": 28765324,
                    "title": "Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28765324"
                },
                {
                    "id": 9765,
                    "pubMedId": 15494073,
                    "title": "Molecular mechanisms of heptaplatin effective against cisplatin-resistant cancer cell lines: less involvement of metallothionein.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15494073"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11761,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a Capmatinib (INC280)-resistant gastric cancer cell line (PMID: 15494073) harboring MET Y1230C also demonstrated resistance when treated with Xalkori (crizotinib) (PMID: 28765324).",
            "molecularProfile": {
                "id": 26644,
                "profileName": "MET Y1230C"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9757,
                    "pubMedId": 28765324,
                    "title": "Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28765324"
                },
                {
                    "id": 9765,
                    "pubMedId": 15494073,
                    "title": "Molecular mechanisms of heptaplatin effective against cisplatin-resistant cancer cell lines: less involvement of metallothionein.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15494073"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11768,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a gastric adenocarcinoma cell line (PMID: 15494073) treated with Xalkori (crizotinib) in culture for several months developed resistance and was found to co-harbor MET Y1230H and MET F1200L(PMID: 28765324).",
            "molecularProfile": {
                "id": 28234,
                "profileName": "MET F1200L MET Y1230H"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9757,
                    "pubMedId": 28765324,
                    "title": "Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28765324"
                },
                {
                    "id": 9765,
                    "pubMedId": 15494073,
                    "title": "Molecular mechanisms of heptaplatin effective against cisplatin-resistant cancer cell lines: less involvement of metallothionein.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15494073"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11769,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a gastric adenocarcinoma cell line (PMID: 15494073) co-harboring MET Y1230H and MET F1200L demonstrated resistance when treated with Capmatinib (INC280) in culture (PMID: 28765324).",
            "molecularProfile": {
                "id": 28234,
                "profileName": "MET F1200L MET Y1230H"
            },
            "therapy": {
                "id": 1065,
                "therapyName": "Capmatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9757,
                    "pubMedId": 28765324,
                    "title": "Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28765324"
                },
                {
                    "id": 9765,
                    "pubMedId": 15494073,
                    "title": "Molecular mechanisms of heptaplatin effective against cisplatin-resistant cancer cell lines: less involvement of metallothionein.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15494073"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11770,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a gastric adenocarcinoma cell line (PMID: 15494073) harboring MET Y1230C was sensitive to treatment with Glesatinib (MGCD265), demonstrating cell growth inhibition in culture (PMID: 28765324).",
            "molecularProfile": {
                "id": 26644,
                "profileName": "MET Y1230C"
            },
            "therapy": {
                "id": 809,
                "therapyName": "Glesatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9757,
                    "pubMedId": 28765324,
                    "title": "Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28765324"
                },
                {
                    "id": 9765,
                    "pubMedId": 15494073,
                    "title": "Molecular mechanisms of heptaplatin effective against cisplatin-resistant cancer cell lines: less involvement of metallothionein.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15494073"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11771,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a gastric adenocarcinoma cell line (PMID: 15494073) co-harboring MET Y1230H and MET F1200L was sensitive to treatment with Glesatinib (MGCD265), demonstrating cell growth inhibition in culture (PMID: 28765324).",
            "molecularProfile": {
                "id": 28234,
                "profileName": "MET F1200L MET Y1230H"
            },
            "therapy": {
                "id": 809,
                "therapyName": "Glesatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9757,
                    "pubMedId": 28765324,
                    "title": "Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28765324"
                },
                {
                    "id": 9765,
                    "pubMedId": 15494073,
                    "title": "Molecular mechanisms of heptaplatin effective against cisplatin-resistant cancer cell lines: less involvement of metallothionein.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15494073"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11832,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, MLN1117 (INK1117) treatment resulted in a partial response in one patient with gastric cancer harboring a PIK3CA mutation (PMID: 28490463; NCT01449370).",
            "molecularProfile": {
                "id": 429,
                "profileName": "PIK3CA mutant"
            },
            "therapy": {
                "id": 1033,
                "therapyName": "MLN1117",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9865,
                    "pubMedId": 28490463,
                    "title": "A First-in-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3K\u03b1 Isoform Inhibitor, in Patients with Advanced Solid Malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28490463"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11984,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, TAS-120 treatment resulted in clinical response in a gastric cancer patient harboring FGFR2 amplification (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 372PD).",
            "molecularProfile": {
                "id": 3147,
                "profileName": "FGFR2 amp"
            },
            "therapy": {
                "id": 1053,
                "therapyName": "Futibatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9948,
                    "pubMedId": null,
                    "title": "First-in-human (FIH) study of TAS-120, a highly selective covalent oral fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced solid tumors",
                    "url": "http://www.esmo.org/content/download/117241/2057634/file/ESMO-2017-Abstract-Book.pdf"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12004,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, sensitivity to treatment with Rogaratinib (BAY 1163877) was demonstrated in patients with a variety of FGFR-expressing solid tumor types, including long lasting stable disease in a patient with FGFR3-positive gastric cancer (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #379P; NCT01976741).",
            "molecularProfile": {
                "id": 9322,
                "profileName": "FGFR3 positive"
            },
            "therapy": {
                "id": 2030,
                "therapyName": "Rogaratinib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9963,
                    "pubMedId": null,
                    "title": "A novel mRNA-based patient selection strategy identifies fibroblast growth factor receptor (FGFR) inhibitor-sensitive tumors: Results from rogaratinib Phase-1 study",
                    "url": "http://www.esmo.org/Conferences/ESMO-2017-Congress/Abstracts"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12054,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, ZW25 treatment resulted in stable disease in 20% (1/5) of patients with ERBB2 (HER2)-positive gastric or esophageal cancers (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #255P; NCT02892123).",
            "molecularProfile": {
                "id": 1187,
                "profileName": "ERBB2 positive"
            },
            "therapy": {
                "id": 6240,
                "therapyName": "ZW25",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9992,
                    "pubMedId": null,
                    "title": "Phase 1 dose-escalation study of single-agent ZW25, a HER2-targeted bispecific antibody, in patients (pts) with HER2-expressing cancers",
                    "url": "http://www.esmo.org/content/download/117241/2057634/file/ESMO-2017-Abstract-Book.pdf"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12075,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, DKN-01 and Taxol (paclitaxel) combination treatment resulted in partial response in 18% (6/34) and stable disease in 32% (11/34) of advanced esophagogastric cancer patients, with a median progression-free survival of 13.7 weeks and an overall survival of 28.4 weeks (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #91P; NCT02013154).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6254,
                "therapyName": "DKN-01 + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10009,
                    "pubMedId": null,
                    "title": "Potential biomarkers of response to DKK1 blockade with DKN-01 in combination with paclitaxel in advanced esophagogastric cancer (EGC) patients (pts)",
                    "url": "http://www.esmo.org/content/download/117241/2057634/file/ESMO-2017-Abstract-Book.pdf"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12327,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Glesatinib (MGCD265) inhibited Met phosphorylation and growth in gastric cancer cells harboring a deletion of MET exon 14 and amplification of the mutant allele in culture, and resulted in tumor regression in cell line xenograft models (PMID: 28765324).",
            "molecularProfile": {
                "id": 26413,
                "profileName": "MET del exon14"
            },
            "therapy": {
                "id": 809,
                "therapyName": "Glesatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 9757,
                    "pubMedId": 28765324,
                    "title": "Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28765324"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 18423,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, gastric cancer cells harboring a MET exon 14 skipping mutation were resistant to Glesatinib (MGCD265) in culture (PMID: 31279006).",
            "molecularProfile": {
                "id": 26413,
                "profileName": "MET del exon14"
            },
            "therapy": {
                "id": 809,
                "therapyName": "Glesatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 16006,
                    "pubMedId": 31279006,
                    "title": "Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In\u00a0Vitro.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31279006"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12330,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Glesatinib (MGCD265) treatment resulted in tumor regression in MET-amplified gastric cancer cell line xenograft models (PMID: 28765324).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 809,
                "therapyName": "Glesatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9757,
                    "pubMedId": 28765324,
                    "title": "Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28765324"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12354,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SYM015 treatment reduced Met expression and phosphorylation, resulted in growth inhibition in culture, and tumor elimination in patient-derived xenograft (PDX) models of gastric cancer with high Met expression (PMID: 28679766).",
            "molecularProfile": {
                "id": 5392,
                "profileName": "MET over exp"
            },
            "therapy": {
                "id": 4322,
                "therapyName": "SYM015",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10340,
                    "pubMedId": 28679766,
                    "title": "Sym015: A Highly Efficacious Antibody Mixture against MET-Amplified Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28679766"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12358,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SYM015 treatment resulted in sustained tumor growth inhibition in cell line xenograft models of gastric cancer harboring MET exon 14 skipping mutations (PMID: 28679766).",
            "molecularProfile": {
                "id": 26413,
                "profileName": "MET del exon14"
            },
            "therapy": {
                "id": 4322,
                "therapyName": "SYM015",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10340,
                    "pubMedId": 28679766,
                    "title": "Sym015: A Highly Efficacious Antibody Mixture against MET-Amplified Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28679766"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12370,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Emibetuzumab (LY2875358) treatment resulted in initial tumor growth inhibition followed by regrowth in cell line xenograft models of gastric cancer harboring MET exon 14 skipping mutations (PMID: 28679766).",
            "molecularProfile": {
                "id": 26413,
                "profileName": "MET del exon14"
            },
            "therapy": {
                "id": 803,
                "therapyName": "Emibetuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 10340,
                    "pubMedId": 28679766,
                    "title": "Sym015: A Highly Efficacious Antibody Mixture against MET-Amplified Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28679766"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12376,
            "approvalStatus": "Phase 0",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a pilot clinical trial, Rapamune (sirolimus) demonstrated modest clinical activity in patients with PIK3CA-mutant gastric cancer (n=3) or hilar cholangiocarcinoma (n=1), including 2 gastric cancer patients harboring PIK3CA E545K and PTEN loss, with a 0% response rate, median progression-free survival of 1.9 months, and median overall survival of 3.6 months (PMID: 28685070).",
            "molecularProfile": {
                "id": 28682,
                "profileName": "PIK3CA E545K PTEN loss"
            },
            "therapy": {
                "id": 917,
                "therapyName": "Sirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "unknown",
            "references": [
                {
                    "id": 10344,
                    "pubMedId": 28685070,
                    "title": "Pilot study of sirolimus in patients with PIK3CA mutant/amplified refractory solid cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28685070"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12377,
            "approvalStatus": "Phase 0",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a pilot clinical trial, Rapamune (sirolimus) demonstrated modest clinical activity in patients with PIK3CA-mutant gastric cancer (n=3) or hilar cholangiocarcinoma (n=1), including a gastric cancer patient harboring PIK3CA E542K and PTEN loss, with a 0% response rate, median progression-free survival of 1.9 months, and median overall survival of 3.6 months (PMID: 28685070).",
            "molecularProfile": {
                "id": 27243,
                "profileName": "PIK3CA E542K PTEN loss"
            },
            "therapy": {
                "id": 917,
                "therapyName": "Sirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "unknown",
            "references": [
                {
                    "id": 10344,
                    "pubMedId": 28685070,
                    "title": "Pilot study of sirolimus in patients with PIK3CA mutant/amplified refractory solid cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28685070"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12606,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (GOLD), addition of Lynparza (olaparib) to Taxol (paclitaxel) did not significantly improve overall survival (12.0 vs 10.0 months, HR=0.73, p=0.25) compared to Taxol (paclitaxel) alone in Asian patients with ATM-negative gastric cancer (PMID: 29103871; NCT01924533).",
            "molecularProfile": {
                "id": 22423,
                "profileName": "ATM negative"
            },
            "therapy": {
                "id": 4807,
                "therapyName": "Olaparib + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 10476,
                    "pubMedId": 29103871,
                    "title": "Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29103871"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12890,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study (AMNESIA-1), assessment of pre-treatment tissue from ERBB2 (HER2)-positive gastric or gastroesophageal cancer patients (defined as HER2 IHC 3+ or HER2 IHC 2+/ISH+) identified MET amplification in 1 patient demonstrating primary resistance to Herceptin (trastuzumab) (PMID: 29208673).",
            "molecularProfile": {
                "id": 29001,
                "profileName": "ERBB2 over exp MET amp"
            },
            "therapy": {
                "id": 947,
                "therapyName": "Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 10846,
                    "pubMedId": 29208673,
                    "title": "Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29208673"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12893,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "n a clinical study (AMNESIA-1), assessment of pre-treatment tumor samples from ERBB2 (HER2)-positive (defined as HER2 IHC 3+ or HER2 IHC 2+/ISH+) gastric or gastroesophageal cancer patients identified MET R988C and amplification of MET in 1 patient demonstrating primary resistance to Herceptin (trastuzumab) (PMID: 29208673).",
            "molecularProfile": {
                "id": 29000,
                "profileName": "ERBB2 over exp MET R988C MET amp"
            },
            "therapy": {
                "id": 947,
                "therapyName": "Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 10846,
                    "pubMedId": 29208673,
                    "title": "Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29208673"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13078,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study (AMNESIA-1), assessment of pre-treatment tumor samples from ERBB2 (HER2)-positive gastric or gastroesophageal cancer patients (defined as HER2 IHC 3+ or HER2 IHC 2+/ISH+) identified PIK3CA mutations in 15% (3/20) of patients demonstrating primary resistance to Herceptin (trastuzumab), including 1 patient harboring PIK3CA N345T (PMID: 29208673).",
            "molecularProfile": {
                "id": 28995,
                "profileName": "ERBB2 over exp PIK3CA N345T"
            },
            "therapy": {
                "id": 947,
                "therapyName": "Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 10846,
                    "pubMedId": 29208673,
                    "title": "Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29208673"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13079,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study (AMNESIA-1), assessment of pre-treatment tumor samples from ERBB2 (HER2)-positive gastric or gastroesophageal cancer patients (defined as HER2 IHC 3+ or HER2 IHC 2+/ISH+) identified PIK3CA mutations in 15% (3/20) of patients demonstrating primary resistance to Herceptin (trastuzumab), including 1 patient harboring PIK3CA H1047L (PMID: 29208673).",
            "molecularProfile": {
                "id": 28996,
                "profileName": "ERBB2 over exp PIK3CA H1047L"
            },
            "therapy": {
                "id": 947,
                "therapyName": "Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 10846,
                    "pubMedId": 29208673,
                    "title": "Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29208673"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13080,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study (AMNESIA-1), assessment of pre-treatment tumor samples from ERBB2 (HER2)-positive gastric or gastroesophageal cancer patients (defined as HER2 IHC 3+ or HER2 IHC 2+/ISH+) identified PIK3CA mutations in 15% (3/20) of patients demonstrating primary resistance to Herceptin (trastuzumab), including 1 patient harboring PIK3CA H1047R (PMID: 29208673).",
            "molecularProfile": {
                "id": 1575,
                "profileName": "ERBB2 over exp PIK3CA H1047R"
            },
            "therapy": {
                "id": 947,
                "therapyName": "Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 10846,
                    "pubMedId": 29208673,
                    "title": "Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29208673"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13081,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study (AMNESIA-1), assessment of pre-treatment tumor samples from ERBB2 (HER2)-positive gastric or gastroesophageal cancer patients (defined as HER2 IHC 3+ or HER2 IHC 2+/ISH+) identified EGFR amplification in 2 patients demonstrating primary resistance to Herceptin (trastuzumab) (PMID: 29208673).",
            "molecularProfile": {
                "id": 28997,
                "profileName": "EGFR amp ERBB2 over exp"
            },
            "therapy": {
                "id": 947,
                "therapyName": "Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 10846,
                    "pubMedId": 29208673,
                    "title": "Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29208673"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13083,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study (AMNESIA-1), assessment of pre-treatment tumor samples from ERBB2 (HER2)-positive gastric or gastroesophageal cancer patients (defined as HER2 IHC 3+ or HER2 IHC 2+/ISH+) identified KRAS G13D in 1 patient demonstrating primary resistance to Herceptin (trastuzumab) (PMID: 29208673).",
            "molecularProfile": {
                "id": 28999,
                "profileName": "ERBB2 over exp KRAS G13D"
            },
            "therapy": {
                "id": 947,
                "therapyName": "Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 10846,
                    "pubMedId": 29208673,
                    "title": "Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29208673"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13084,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study (AMNESIA-1), assessment of pre-treatment tumor samples from ERBB2 (HER2)-positive gastric or gastroesophageal cancer patients (defined as HER2 IHC 3+ or HER2 IHC 2+/ISH+) identified KRAS A146V and BRAF V600E in 1 patient demonstrating primary resistance to Herceptin (trastuzumab) (PMID: 29208673).",
            "molecularProfile": {
                "id": 28998,
                "profileName": "BRAF V600E ERBB2 over exp KRAS A146V"
            },
            "therapy": {
                "id": 947,
                "therapyName": "Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 10846,
                    "pubMedId": 29208673,
                    "title": "Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29208673"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13149,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, MEDI4276 treatment resulted in complete response in 1 patient with breast cancer, partial response in 1 patient with breast cancer, and stable disease in 12 patients with Erbb2 (Her2)-positive breast or gastric cancer (Annals of Oncology, Volume 29, Issue suppl_3, 1 March 2018, abstract 470; NCT02576548).",
            "molecularProfile": {
                "id": 1187,
                "profileName": "ERBB2 positive"
            },
            "therapy": {
                "id": 6763,
                "therapyName": "MEDI4276",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10992,
                    "pubMedId": null,
                    "title": "Phase 1 study of bispecific HER2 antibody-drug conjugate MEDI4276 in patients with advanced HER2-positive breast or gastric cancer",
                    "url": "https://academic.oup.com/annonc/article/29/suppl_3/mdy048.005/4917517"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13580,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SCC244 inhibited Met activity, downstream signaling, and cell proliferation in gastric cancer cells harboring MET amplification in culture, and inhibited tumor growth in cell line xenograft models (PMID: 29237805).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 6844,
                "therapyName": "SCC244",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11200,
                    "pubMedId": 29237805,
                    "title": "Preclinical Evaluation of SCC244 (Glumetinib), a Novel, Potent, and Highly Selective Inhibitor of c-Met in MET-dependent Cancer Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29237805"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13595,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MI130004 inhibited proliferation of ERBB2 (HER2)-positive gastric cancer cells in culture, and led to decreased tumor volume and improved survival in cell line xenograft models (PMID: 29440297).",
            "molecularProfile": {
                "id": 1187,
                "profileName": "ERBB2 positive"
            },
            "therapy": {
                "id": 6868,
                "therapyName": "MI130004",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11220,
                    "pubMedId": 29440297,
                    "title": "MI130004, a Novel Antibody-Drug Conjugate Combining Trastuzumab with a Molecule of Marine Origin, Shows Outstanding In Vivo Activity against HER2-Expressing Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29440297"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13678,
            "approvalStatus": "Guideline",
            "evidenceType": "Risk Factor",
            "efficacyEvidence": "Germline mutations in STK11 result in Peutz Jeghers syndrome, which is associated with increased risk of developing gastric cancer (NCCN.org).",
            "molecularProfile": {
                "id": 1246,
                "profileName": "STK11 mutant"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 13680,
            "approvalStatus": "Guideline",
            "evidenceType": "Risk Factor",
            "efficacyEvidence": "Germline mutations in SMAD4 or BMPR1A result in juvenile polyposis syndrome, which is associated with increased risk of developing gastric cancer (NCCN.org).",
            "molecularProfile": {
                "id": 19842,
                "profileName": "SMAD4 mutant"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 13681,
            "approvalStatus": "Guideline",
            "evidenceType": "Risk Factor",
            "efficacyEvidence": "Germline mutations in the SMAD4 or BMPR1A genes result in juvenile polyposis syndrome, which is associated with increased risk of developing gastric cancer (NCCN.org).",
            "molecularProfile": {
                "id": 29373,
                "profileName": "BMPR1A mutant"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 13682,
            "approvalStatus": "Guideline",
            "evidenceType": "Risk Factor",
            "efficacyEvidence": "Germline mutations in MLH1 result in Lynch syndrome, which is associated with increased risk of early onset of gastric cancer (NCCN.org).",
            "molecularProfile": {
                "id": 17286,
                "profileName": "MLH1 mutant"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 13683,
            "approvalStatus": "Guideline",
            "evidenceType": "Risk Factor",
            "efficacyEvidence": "Germline mutations in MSH2 result in Lynch syndrome, which is associated with increased risk of early onset of gastric cancer (NCCN.org).",
            "molecularProfile": {
                "id": 17287,
                "profileName": "MSH2 mutant"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 13684,
            "approvalStatus": "Guideline",
            "evidenceType": "Risk Factor",
            "efficacyEvidence": "Germline deletion of EPCAM is implicated in Lynch syndrome, which is associated with increased risk of early onset of gastric cancer (NCCN.org).",
            "molecularProfile": {
                "id": 29374,
                "profileName": "EPCAM del"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 13795,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Derazantinib (ARQ 087) inhibited Fgfr signaling and growth of gastric cancer cells harboring FGFR2 amplification and PDHX-FGFR2 fusion in culture, resulted in tumor regression in cell line xenograft models (PMID: 27627808).",
            "molecularProfile": {
                "id": 26313,
                "profileName": "FGFR2 fusion FGFR2 amp"
            },
            "therapy": {
                "id": 2900,
                "therapyName": "Derazantinib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11276,
                    "pubMedId": 27627808,
                    "title": "Preclinical Activity of ARQ 087, a Novel Inhibitor Targeting FGFR Dysregulation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27627808"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13797,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Derazantinib (ARQ 087) inhibited Fgfr signaling and growth of gastric cancer cells harboring FGFR2 amplification in culture (PMID: 27627808).",
            "molecularProfile": {
                "id": 3147,
                "profileName": "FGFR2 amp"
            },
            "therapy": {
                "id": 2900,
                "therapyName": "Derazantinib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11276,
                    "pubMedId": 27627808,
                    "title": "Preclinical Activity of ARQ 087, a Novel Inhibitor Targeting FGFR Dysregulation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27627808"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13869,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Camrelizumab (SHR-1210) demonstrated safety and preliminary anti-tumor activity, resulted in partial response in 37.5% (3/8) of patients with gastric cancer (J Clin Onc. 2017 35:15_suppl, e15572-e15572; NCT02742935).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6137,
                "therapyName": "Camrelizumab",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9759,
                    "pubMedId": null,
                    "title": "Phase I study of the anti-PD-1 antibody SHR-1210 in patients with advanced solid tumors.",
                    "url": "http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.e15572"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 14216,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (TAGS) that supproted FDA approval, Lonsurf (trifluridine/tipiracil hydrochloride) treatment resulted in improved overall survival (5.7 vs 3.6 months, HR=0.69, p=0.00029) compared to placebo in patients with heavily pretreated metastatic or advanced gastric cancer or gastroesophageal junction adenocarcinoma (PMID: 30355453; NCT02500043).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2426,
                "therapyName": "trifluridine/tipiracil hydrochloride",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 11519,
                    "pubMedId": null,
                    "title": "Overall Survival Results from a Phase III Trial of Trifluridine/Tipracial vs Placebo in Patients with Metastatic Gastric Cancer Refractory to Standard Therapies (TAGS).",
                    "url": "https://academic.oup.com/annonc/issue/29/suppl_5"
                },
                {
                    "id": 14281,
                    "pubMedId": 30355453,
                    "title": "Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30355453"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 14937,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ERBB2 (HER2)-positive ovarian xenograft model was sensitive to treatment with ARX-788, resulting in tumor regression (Cancer Res 2015;75(15 Suppl):Abstract nr 639).",
            "molecularProfile": {
                "id": 1187,
                "profileName": "ERBB2 positive"
            },
            "therapy": {
                "id": 7199,
                "therapyName": "ARX-788",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11818,
                    "pubMedId": null,
                    "title": "Abstract 639: Site specific conjugation of ARX-788, an antibody drug conjugate (ADC) targeting HER2, generates a potent and stable targeted therapeutic for multiple cancers",
                    "url": "http://cancerres.aacrjournals.org/content/75/15_Supplement/639"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15321,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Prognostic",
            "efficacyEvidence": "In multiple clinical studies, overexpression of Epha3 in gastric cancer patients was associated with poor prognosis (PMID: 22350700) and decreased relapse-free survival (PMID: 28465671, PMID: 24908114).",
            "molecularProfile": {
                "id": 9464,
                "profileName": "EPHA3 over exp"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 13074,
                    "pubMedId": 28465671,
                    "title": "High expression of EphA3 (erythropoietin-producing hepatocellular A3) in gastric cancer is associated with metastasis and poor survival.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28465671"
                },
                {
                    "id": 13076,
                    "pubMedId": 24908114,
                    "title": "Overexpression of Ephrin A2 receptors in cancer stromal cells is a prognostic factor for the relapse of gastric cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24908114"
                },
                {
                    "id": 13077,
                    "pubMedId": 22350700,
                    "title": "Aberrant expression of EphA3 in gastric carcinoma: correlation with tumor angiogenesis and survival.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22350700"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15524,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, gastric cancer cells harboring a MET exon 14 splice site mutation demonstrated some resistance to treatment with Xalkori (crizotinib) when overexpressing wild-type Kras in culture (PMID: 30072474).",
            "molecularProfile": {
                "id": 31074,
                "profileName": "KRAS over exp MET del exon14"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 13406,
                    "pubMedId": 30072474,
                    "title": "Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30072474"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15968,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib trial, combined Camrelizumab (SHR-1210) and Apatinib (YN968D1) treatment resulted in an overall response rate of 17.4% (4/23), a disease control rate of 78.3% (18/23), a median progression-free survival (PFS) of 2.9 months, and an overall survival of 11.4 months in evaluable patients with gastric or gastroesophageal junction cancer (PMID: 30348638; NCT02942329).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 7840,
                "therapyName": "Apatinib + Camrelizumab",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 14095,
                    "pubMedId": 30348638,
                    "title": "Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30348638"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16149,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, patients with esophagogastric cancer (n=126) and a high tumor mutational burden (TMB) (>8.8 mutations/Mb) demonstrated an improved overall survival and progression-free survival compared to those patients with a low TMB when treated with an unspecified PD-1 antibody (PMID: 30643254).",
            "molecularProfile": {
                "id": 29716,
                "profileName": "TMB high"
            },
            "therapy": {
                "id": 3890,
                "therapyName": "unspecified PD-1 antibody",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14282,
                    "pubMedId": 30643254,
                    "title": "Tumor mutational load predicts survival after immunotherapy across multiple cancer types.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30643254"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16151,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, patients with esophagogastric cancer (n=126) and a high tumor mutational burden (TMB) (>8.8 mutations/Mb) demonstrated an improved overall survival and progression-free survival compared to those patients with a low TMB when treated with an unspecified PD-L1 antibody (PMID: 30643254).",
            "molecularProfile": {
                "id": 29716,
                "profileName": "TMB high"
            },
            "therapy": {
                "id": 5248,
                "therapyName": "unspecified PD-L1 antibody",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14282,
                    "pubMedId": 30643254,
                    "title": "Tumor mutational load predicts survival after immunotherapy across multiple cancer types.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30643254"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16153,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, patients with esophagogastric cancer (n=126) and a high tumor mutational burden (TMB) (>8.8 mutations/Mb) demonstrated an improved overall survival and progression-free survival compared to those patients with a low TMB when treated with a combination of an unspecified CTLA-4 antibody and unspecified PD-1 antibody (PMID: 30643254).",
            "molecularProfile": {
                "id": 29716,
                "profileName": "TMB high"
            },
            "therapy": {
                "id": 6804,
                "therapyName": "unspecified CTLA4 antibody + unspecified PD-1 antibody",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14282,
                    "pubMedId": 30643254,
                    "title": "Tumor mutational load predicts survival after immunotherapy across multiple cancer types.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30643254"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16155,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, patients with esophagogastric cancer (n=126) and a high tumor mutational burden (TMB) (>8.8 mutations/Mb) demonstrated an improved overall survival and progression-free survival compared to those patients with a low TMB when treated with a combination of an unspecified CTLA-4 antibody and unspecified PD-L1 antibody (PMID: 30643254).",
            "molecularProfile": {
                "id": 29716,
                "profileName": "TMB high"
            },
            "therapy": {
                "id": 7906,
                "therapyName": "unspecified CTLA4 antibody + unspecified PD-L1 antibody",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14282,
                    "pubMedId": 30643254,
                    "title": "Tumor mutational load predicts survival after immunotherapy across multiple cancer types.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30643254"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16372,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ODM-203 inhibited FGFR signaling and proliferation in a gastric cancer cell line with amplification of FGFR2, and inhibited tumor growth in xenograft models (PMID: 30301864).",
            "molecularProfile": {
                "id": 3147,
                "profileName": "FGFR2 amp"
            },
            "therapy": {
                "id": 8010,
                "therapyName": "ODM-203",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14470,
                    "pubMedId": 30301864,
                    "title": "ODM-203, a Selective Inhibitor of FGFR and VEGFR, Shows Strong Antitumor Activity, and Induces Antitumor Immunity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30301864"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16496,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ERBB2 (HER2)-amplified gastric cancer cells overexpressing Nfe2l2 and Rps6 demonstrated resistance in both culture and cell line xenograft models when treated with Tykerb (lapatinib) (PMID: 30504425).",
            "molecularProfile": {
                "id": 31652,
                "profileName": "ERBB2 amp NFE2L2 over exp RPS6 over exp"
            },
            "therapy": {
                "id": 787,
                "therapyName": "Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 14570,
                    "pubMedId": 30504425,
                    "title": "NRF2 through RPS6 Activation Is Related to Anti-HER2 Drug Resistance in HER2-Amplified Gastric Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30504425"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16498,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ERBB2 (HER2)-amplified gastric cancer cells overexpressing Nfe2l2 and Rps6 demonstrated resistance to treatment with Herceptin (trastuzumab) in culture (PMID: 30504425).",
            "molecularProfile": {
                "id": 31652,
                "profileName": "ERBB2 amp NFE2L2 over exp RPS6 over exp"
            },
            "therapy": {
                "id": 947,
                "therapyName": "Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 14570,
                    "pubMedId": 30504425,
                    "title": "NRF2 through RPS6 Activation Is Related to Anti-HER2 Drug Resistance in HER2-Amplified Gastric Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30504425"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16500,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ERBB2 (HER2)-amplified gastric cancer cells overexpressing Nfe2l2 and Rps6 did not respond to treatment with Saracatinib (AZD0530) in culture (PMID: 30504425).",
            "molecularProfile": {
                "id": 31652,
                "profileName": "ERBB2 amp NFE2L2 over exp RPS6 over exp"
            },
            "therapy": {
                "id": 912,
                "therapyName": "Saracatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 14570,
                    "pubMedId": 30504425,
                    "title": "NRF2 through RPS6 Activation Is Related to Anti-HER2 Drug Resistance in HER2-Amplified Gastric Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30504425"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16501,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ERBB2 (HER2)-amplified gastric cancer cells overexpressing Nfe2l2 and Rps6 demonstrated non-significant reduced viability when treated with Afinitor (everolimus) in culture (PMID: 30504425).",
            "molecularProfile": {
                "id": 31652,
                "profileName": "ERBB2 amp NFE2L2 over exp RPS6 over exp"
            },
            "therapy": {
                "id": 735,
                "therapyName": "Everolimus",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 14570,
                    "pubMedId": 30504425,
                    "title": "NRF2 through RPS6 Activation Is Related to Anti-HER2 Drug Resistance in HER2-Amplified Gastric Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30504425"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16502,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ERBB2 (HER2)-amplified gastric cancer cells overexpressing Nfe2l2 and Rps6 demonstrated only a minimal decrease in viability when treated with Pimasertib (MSC1936369B) in culture (PMID: 30504425).",
            "molecularProfile": {
                "id": 31652,
                "profileName": "ERBB2 amp NFE2L2 over exp RPS6 over exp"
            },
            "therapy": {
                "id": 871,
                "therapyName": "Pimasertib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 14570,
                    "pubMedId": 30504425,
                    "title": "NRF2 through RPS6 Activation Is Related to Anti-HER2 Drug Resistance in HER2-Amplified Gastric Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30504425"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16505,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination treatment of GSK2126458 and Tykerb (lapatinib) in ERBB2 (HER2)-amplified gastric cancer cells overexpressing Nfe2l2 and Rps6 demonstrated reduced cell viability in culture and decreased tumor growth and expression of Rps6 and Nfe2l2 in cell line xenograft models (PMID: 30504425).",
            "molecularProfile": {
                "id": 31652,
                "profileName": "ERBB2 amp NFE2L2 over exp RPS6 over exp"
            },
            "therapy": {
                "id": 8070,
                "therapyName": "GSK2126458 + Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14570,
                    "pubMedId": 30504425,
                    "title": "NRF2 through RPS6 Activation Is Related to Anti-HER2 Drug Resistance in HER2-Amplified Gastric Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30504425"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16662,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, co-amplification of EGFR and ERBB2 (HER2) was identified at the time of progression in a patient with ERBB2 (HER2)-positive gastric cancer who initially demonstrated a short response to the combination therapy of Herceptin (trastuzumab), Adrucil (fluorouracil), and Eloxatin (oxaliplatin), but then progression at 7 months (PMID: 30463996; NCT01522768).",
            "molecularProfile": {
                "id": 22032,
                "profileName": "EGFR amp ERBB2 amp"
            },
            "therapy": {
                "id": 8124,
                "therapyName": "Fluorouracil + Oxaliplatin + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 14704,
                    "pubMedId": 30463996,
                    "title": "EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30463996"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 16669,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, a gastric cancer patient with co-amplification of ERBB2 (HER2) and EGFR initially responded to treatment with Gilotrif (afatinib), but progressed at 16 weeks, and post-treatment tumor profiling of the progressing disease sites, the liver lesions, identified ERBB2 (HER2) amplification, PTEN P95R, and CCND3 amplification, but not EGFR amplification (PMID: 30463996; NCT30463996).",
            "molecularProfile": {
                "id": 31743,
                "profileName": "CCND3 amp ERBB2 amp PTEN P95R"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 14704,
                    "pubMedId": 30463996,
                    "title": "EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30463996"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16677,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, a gastric cancer patient with co-amplification of EGFR and ERBB2 (HER2) who previously progressed on a combination therapy with Herceptin (trastuzumab) demonstrated a 37% tumor regression when treated with Gilotrif (afatinib) (PMID: 30463996; NCT01522768).",
            "molecularProfile": {
                "id": 22032,
                "profileName": "EGFR amp ERBB2 amp"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14704,
                    "pubMedId": 30463996,
                    "title": "EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30463996"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16683,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, a gastric cancer patient with ERBB2 (HER2) amplification demonstrated a response for 24 months when treated with the combination of Adrucil (fluorouracil), Eloxatin (oxaliplatin), and Herceptin (trastuzumab) (PMID: 30463996; NCT01522768).",
            "molecularProfile": {
                "id": 531,
                "profileName": "ERBB2 amp"
            },
            "therapy": {
                "id": 8124,
                "therapyName": "Fluorouracil + Oxaliplatin + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14704,
                    "pubMedId": 30463996,
                    "title": "EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30463996"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16684,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, a gastric cancer patient with ERBB2 (HER2) amplification who progressed on previous therapy demonstrated a 22% regression in a metastatic site when treated with a combination of Gilotrif (afatinib) and Herceptin (trastuzumab) (PMID: 30463996; NCT01522768).",
            "molecularProfile": {
                "id": 531,
                "profileName": "ERBB2 amp"
            },
            "therapy": {
                "id": 1106,
                "therapyName": "Afatinib + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14704,
                    "pubMedId": 30463996,
                    "title": "EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30463996"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16770,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TAS0728 inhibited Erbb2 downstream signaling and proliferation of ERBB2 (HER2) amplified gastric cancer cells in culture, and induced tumor regression in cell line xenograft models (PMID: 30787176).",
            "molecularProfile": {
                "id": 531,
                "profileName": "ERBB2 amp"
            },
            "therapy": {
                "id": 8170,
                "therapyName": "TAS0728",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14833,
                    "pubMedId": 30787176,
                    "title": "TAS0728, A Covalent-binding, HER2-selective Kinase Inhibitor Shows Potent Antitumor Activity in Preclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30787176"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16838,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TPX-0022 inhibits phosphorylation of Met and downstream signaling, resulted in growth inhibition of MET amplified gastric cancer cell lines in culture and in cell line xenograft models (Proceedings of the American Association for Cancer Research, Vol 60, Mar 2019, Abstract #1321).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 8205,
                "therapyName": "TPX-0022",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14951,
                    "pubMedId": null,
                    "title": "TPX-0022, a polypharmacology inhibitor of MET/CSF1R/SRC for treatment of cancers with abnormal HGF/MET signaling.",
                    "url": "https://www.aacr.org/Documents/AACR_2019_Proceedings.pdf"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17507,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I clinical trial, treatment with GC1118 resulted in an overall response rate of 8% (1/12; partial response), stable disease in 17% (2/12), and a median progression-free survival of 6.7 weeks in patients with EGFR-overexpressing gastric cancer (PMID: 31164456; NCT02352571).",
            "molecularProfile": {
                "id": 2419,
                "profileName": "EGFR over exp"
            },
            "therapy": {
                "id": 2913,
                "therapyName": "GC1118",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15519,
                    "pubMedId": 31164456,
                    "title": "A First-in-Human Phase I Study of GC1118, a Novel Anti-Epidermal Growth Factor Receptor Antibody, in Patients with Advanced Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31164456"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17725,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I/II trial, Toripalimab (JS001) treatment resulted in an objective response rate (ORR) of 12.1% (7/58, 7 partial responses) and a disease control rate of 39.7% (23/58) in patients with advanced gastric cancer, the TMB-high group demonstrated improved ORR (4/12, 33.3% vs 3/42, 7.1%, p=0.017) and overall survival (14.6 vs 4.0 months, HR=0.48, p=0.038) compared to the TMB-low group (PMID: 31236579; NCT02915432).",
            "molecularProfile": {
                "id": 29716,
                "profileName": "TMB high"
            },
            "therapy": {
                "id": 5891,
                "therapyName": "Toripalimab",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15752,
                    "pubMedId": 31236579,
                    "title": "Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31236579"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17726,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I/II trial, Toripalimab (JS001) treatment resulted in an objective response rate (ORR) of 12.1% (7/58, 7 partial responses) and a disease control rate of 39.7% (23/58) in patients with advanced gastric cancer, the CD274 (PD-L1)-positive group demonstrated improved ORR (3/8, 37.5% vs 4/47, 8.5%, p=0.023) but not overall survival (12.1 vs 5.3 months, p=0.45) compared to the CD274 (PD-L1)-negative group (PMID: 31236579; NCT02915432).",
            "molecularProfile": {
                "id": 4746,
                "profileName": "CD274 positive"
            },
            "therapy": {
                "id": 5891,
                "therapyName": "Toripalimab",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 15752,
                    "pubMedId": 31236579,
                    "title": "Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31236579"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17728,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I/II trial, Toripalimab (JS001) in combination with Eloxatin (oxaliplatin) and Xeloda (capecitabine) resulted in an objective response rate (ORR) of 66.7% (12/18, 1 complete response, 11 partial responses) and a disease control rate of 88.9% (16/18) in patients with chemotherapy-naive advanced gastric cancer, with a progression-free survival of 5.8 months and overall survival not reached, same ORRs (66.7%) were observed in CD274 (PD-L1)-positive and -negative groups (PMID: 31236579; NCT02915432).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 8598,
                "therapyName": "Capecitabine + Oxaliplatin + Toripalimab",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 15752,
                    "pubMedId": 31236579,
                    "title": "Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31236579"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 17729,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I/II trial, patients with TMB low and CD274 (PD-L1)-negative advanced gastric cancer (n=33) demonstrated worse objective response rate (3.0% vs 33.3%), progression-free survival (1.9 vs 2.7 months), and overall survival (4 vs 12.1 months) compared to patients with TMB high or CD274 (PD-L1)-positive tumors (n=18) in response to Toripalimab (JS001) treatment (PMID: 31236579; NCT02915432).",
            "molecularProfile": {
                "id": 32762,
                "profileName": "CD274 neg TMB low"
            },
            "therapy": {
                "id": 5891,
                "therapyName": "Toripalimab",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 15752,
                    "pubMedId": 31236579,
                    "title": "Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31236579"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 18416,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Xalkori (crizotinib) inhibited growth of gastric cancer cells harboring a MET exon 14 skipping mutation in culture (PMID: 31279006).",
            "molecularProfile": {
                "id": 26413,
                "profileName": "MET del exon14"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16006,
                    "pubMedId": 31279006,
                    "title": "Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In\u00a0Vitro.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31279006"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18417,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Capmatinib (INC280) inhibited growth of gastric cancer cells harboring a MET exon 14 skipping mutation in culture (PMID: 31279006).",
            "molecularProfile": {
                "id": 26413,
                "profileName": "MET del exon14"
            },
            "therapy": {
                "id": 1065,
                "therapyName": "Capmatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16006,
                    "pubMedId": 31279006,
                    "title": "Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In\u00a0Vitro.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31279006"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18418,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tepotinib (MSC2156119J) inhibited growth of gastric cancer cells harboring a MET exon 14 skipping mutation in culture (PMID: 31279006).",
            "molecularProfile": {
                "id": 26413,
                "profileName": "MET del exon14"
            },
            "therapy": {
                "id": 1398,
                "therapyName": "Tepotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16006,
                    "pubMedId": 31279006,
                    "title": "Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In\u00a0Vitro.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31279006"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18419,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Cometriq (Cabometyx, cabozantinib) inhibited growth of gastric cancer cells harboring a MET exon 14 skipping mutation in culture (PMID: 31279006).",
            "molecularProfile": {
                "id": 26413,
                "profileName": "MET del exon14"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16006,
                    "pubMedId": 31279006,
                    "title": "Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In\u00a0Vitro.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31279006"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18420,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, gastric cancer cells harboring a MET exon 14 skipping mutation demonstrated decreased response to Savolitinib (AZD6094) compared to cells expressing sensitizing MET mutations in culture (PMID: 31279006).",
            "molecularProfile": {
                "id": 26413,
                "profileName": "MET del exon14"
            },
            "therapy": {
                "id": 2161,
                "therapyName": "Savolitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 16006,
                    "pubMedId": 31279006,
                    "title": "Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In\u00a0Vitro.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31279006"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 18421,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, gastric cancer cells harboring a MET exon 14 skipping mutation demonstrated decreased response to Merestinib (LY2801653) compared to cells expressing sensitizing MET mutations in culture (PMID: 31279006).",
            "molecularProfile": {
                "id": 26413,
                "profileName": "MET del exon14"
            },
            "therapy": {
                "id": 1030,
                "therapyName": "Merestinib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 16006,
                    "pubMedId": 31279006,
                    "title": "Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In\u00a0Vitro.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31279006"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 18422,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, gastric cancer cells harboring a MET exon 14 skipping mutation demonstrated decreased response to Tivantinib (ARQ197) in culture (PMID: 31279006).",
            "molecularProfile": {
                "id": 26413,
                "profileName": "MET del exon14"
            },
            "therapy": {
                "id": 636,
                "therapyName": "Tivantinib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 16006,
                    "pubMedId": 31279006,
                    "title": "Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In\u00a0Vitro.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31279006"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 18781,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, OMO-1 inhibited tumor growth in a cell line xenograft model of MET-amplified gastric cancer (Cancer Res 2018;78(13 Suppl):Abstract nr 4791).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 8846,
                "therapyName": "OMO-1",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16455,
                    "pubMedId": null,
                    "title": "OMO-1, a potent, highly selective, orally bioavailable, MET kinase inhibitor with a favorable preclinical toxicity profile, shows both monotherapy activity, against MET pathway-driven tumors, and EGFR TKI combination activity in acquired resistance models",
                    "url": "https://cancerres.aacrjournals.org/content/78/13_Supplement/4791"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18785,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, OMO-1 inhibited tumor growth in a cell line xenograft model of gastric cancer with a MET exon 14 skipping mutation (Cancer Res 2018;78(13 Suppl):Abstract nr 4791).",
            "molecularProfile": {
                "id": 26413,
                "profileName": "MET del exon14"
            },
            "therapy": {
                "id": 8846,
                "therapyName": "OMO-1",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16455,
                    "pubMedId": null,
                    "title": "OMO-1, a potent, highly selective, orally bioavailable, MET kinase inhibitor with a favorable preclinical toxicity profile, shows both monotherapy activity, against MET pathway-driven tumors, and EGFR TKI combination activity in acquired resistance models",
                    "url": "https://cancerres.aacrjournals.org/content/78/13_Supplement/4791"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19378,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Poteligeo (mogamulizumab-kpkc) and Opdivo (nivolumab) combination treatment demonstrated acceptable safety, resulted in an objective response rate of 0% (0/15) and a disease control rate of 27% (4/15) in immunotherapy-naive patients with advanced or metastatic gastric cancer, response occurred regardless of PD-L1, CCR4, CD8 expression levels and tumor mutational burden (PMID: 31455681; NCT02476123).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3843,
                "therapyName": "Mogamulizumab + Nivolumab",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 16935,
                    "pubMedId": 31455681,
                    "title": "A Phase I Study of the Anti-CC Chemokine Receptor 4 Antibody, Mogamulizumab, in Combination with Nivolumab in Patients with Advanced or Metastatic Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31455681"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 19458,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, FGF401 inhibited proliferation of a FGF19, KLB, and FGFR4-positive gastric cancer cell line in culture, and inhibited tumor growth in a patient-derived xenograft (PDX) model (PMID: 31409633).",
            "molecularProfile": {
                "id": 34158,
                "profileName": "FGF19 pos FGFR4 pos KLB pos"
            },
            "therapy": {
                "id": 2031,
                "therapyName": "FGF401",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17101,
                    "pubMedId": 31409633,
                    "title": "FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31409633"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19464,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, FGF401 did not inhibit tumor growth in a FGFR4-positive, KLB-negative, and FGF19 amplified and overexpressing patient-derived xenograft (PDX) model of gastric cancer (PMID: 31409633).",
            "molecularProfile": {
                "id": 34161,
                "profileName": "FGF19 amp FGF19 over exp FGFR4 pos KLB neg"
            },
            "therapy": {
                "id": 2031,
                "therapyName": "FGF401",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 17101,
                    "pubMedId": 31409633,
                    "title": "FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31409633"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19492,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TR1801-ADC treatment inhibited tumor growth and induced regression in patient-derived xenograft (PDX) models of gastric cancer with high MET expression (Cancer Res 2019; 79(13 Suppl): Abstract nr 225).",
            "molecularProfile": {
                "id": 5392,
                "profileName": "MET over exp"
            },
            "therapy": {
                "id": 9054,
                "therapyName": "TR1801-ADC",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17103,
                    "pubMedId": null,
                    "title": "TR1801-ADC, an optimized anti cMet PBD ADC with high efficacy in solid tumors of the GI tract and head & neck cancer",
                    "url": "https://cancerres.aacrjournals.org/content/79/13_Supplement/225"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19730,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, OBI-999 treatment inhibited tumor growth in a Globo H-expressing gastric cancer cell line xenograft model (Cancer Res 2019;79(13 Suppl):Abstract nr 4815).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 9197,
                "therapyName": "OBI-999",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 17532,
                    "pubMedId": null,
                    "title": "Novel Globo H targeting antibody-drug conjugate with binding specificity and anti-tumor efficacy in multiple cancer types",
                    "url": "https://cancerres.aacrjournals.org/content/79/13_Supplement/4815"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 19885,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CGX1321 treatment inhibited tumor growth and led to decreased expression of AXIN in a patient-derived xenograft (PDX) model of gastric cancer harboring EMC2-RSPO2 (PMID: 30250044).",
            "molecularProfile": {
                "id": 34654,
                "profileName": "EMC2 - RSPO2"
            },
            "therapy": {
                "id": 6584,
                "therapyName": "CGX1321",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17432,
                    "pubMedId": 30250044,
                    "title": "Identification of RSPO2 Fusion Mutations and Target Therapy Using a Porcupine Inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30250044"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19886,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CGX1321 treatment inhibited tumor growth and led to decreased expression of AXIN in a patient-derived xenograft (PDX) model of gastric cancer harboring HNF4G-RSPO2 (PMID: 30250044).",
            "molecularProfile": {
                "id": 34651,
                "profileName": "HNF4G - RSPO2"
            },
            "therapy": {
                "id": 6584,
                "therapyName": "CGX1321",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17432,
                    "pubMedId": 30250044,
                    "title": "Identification of RSPO2 Fusion Mutations and Target Therapy Using a Porcupine Inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30250044"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19960,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, XMT-1522 demonstrated improved efficacy compared to Kadcyla (ado-trastuzumab emtansine), inhibited growth of Erbb2 (Her2)-positive gastric cancer cell lines in culture, resulted in tumor regression and prolonged survival in cell line xenograft models (PMID: 31292166).",
            "molecularProfile": {
                "id": 1187,
                "profileName": "ERBB2 positive"
            },
            "therapy": {
                "id": 5834,
                "therapyName": "XMT-1522",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17641,
                    "pubMedId": 31292166,
                    "title": "A Novel Anti-HER2 Antibody-Drug Conjugate XMT-1522 for HER2-Positive Breast and Gastric Cancers Resistant to Trastuzumab Emtansine.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31292166"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19982,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Infigratinib (BGJ398) treatment inhibited tumor growth in a patient-derived xenograft (PDX) model of gastric cancer harboring FGFR2-WDR11 fusion (Cancer Res 2019;79(13 Suppl):Abstract nr 2206).",
            "molecularProfile": {
                "id": 34739,
                "profileName": "FGFR2 - WDR11"
            },
            "therapy": {
                "id": 674,
                "therapyName": "BGJ398",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16500,
                    "pubMedId": null,
                    "title": "Anti-tumor activity of infigratinib, a potent and selective inhibitor of FGFR1, FGFR2 and FGFR3, in FGFR fusion-positive cholangiocarcinoma and other solid tumors",
                    "url": "https://cancerres.aacrjournals.org/content/79/13_Supplement/2206"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20026,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Vitrakvi (larotrectinib) is included in guidelines as second-line or subsequent therapy for patients with advanced or metastatic gastric cancer with an NTRK fusion (NCCN.org).",
            "molecularProfile": {
                "id": 2904,
                "profileName": "NTRK1 fusion"
            },
            "therapy": {
                "id": 2650,
                "therapyName": "Larotrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 20027,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Vitrakvi (larotrectinib) is included in guidelines as second-line or subsequent therapy for patients with advanced or metastatic gastric cancer with an NTRK fusion (NCCN.org).",
            "molecularProfile": {
                "id": 2908,
                "profileName": "NTRK2 fusion"
            },
            "therapy": {
                "id": 2650,
                "therapyName": "Larotrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 20028,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Vitrakvi (larotrectinib) is included in guidelines as second-line or subsequent therapy for patients with advanced or metastatic gastric cancer with an NTRK fusion (NCCN.org).",
            "molecularProfile": {
                "id": 2909,
                "profileName": "NTRK3 fusion"
            },
            "therapy": {
                "id": 2650,
                "therapyName": "Larotrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 20029,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Rozlytrek (entrectinib) is included in guidelines as second-line or subsequent therapy for patients with advanced or metastatic gastric cancer with an NTRK fusion (NCCN.org).",
            "molecularProfile": {
                "id": 2904,
                "profileName": "NTRK1 fusion"
            },
            "therapy": {
                "id": 1455,
                "therapyName": "Entrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 20030,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Rozlytrek (entrectinib) is included in guidelines as second-line or subsequent therapy for patients with advanced or metastatic gastric cancer with an NTRK fusion (NCCN.org).",
            "molecularProfile": {
                "id": 2908,
                "profileName": "NTRK2 fusion"
            },
            "therapy": {
                "id": 1455,
                "therapyName": "Entrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 20031,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Rozlytrek (entrectinib) is included in guidelines as second-line or subsequent therapy for patients with advanced or metastatic gastric cancer with an NTRK fusion (NCCN.org).",
            "molecularProfile": {
                "id": 2909,
                "profileName": "NTRK3 fusion"
            },
            "therapy": {
                "id": 1455,
                "therapyName": "Entrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 20478,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (ATTRACTION-4), the combination therapy of Xeloda (capecitabine), Opdivo (nivolumab), Eloxatin (oxaliplatin), and TS-1 (tegafur-gimeracil-oteracil potassium) was well-tolerated and resulted in an objective response rate of 76.5% (13/17), a median progression-free survival of 10.6 months, and a median overall survival that was not yet reached in patients with either gastric cancer or gastroesophageal junction cancer (PMID: 30566590; NCT02746796).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 9367,
                "therapyName": "Capecitabine + Nivolumab + Oxaliplatin + TS-1",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 17859,
                    "pubMedId": 30566590,
                    "title": "Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30566590"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 20757,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK690693 treatment inhibited phosphorylation of Akt and S6, reduced viability and induced apoptosis in ARID1A knockdown gastric cancer cell lines expressing AKT1 in culture (PMID: 28860825).",
            "molecularProfile": {
                "id": 35327,
                "profileName": "AKT1 pos ARID1A dec exp"
            },
            "therapy": {
                "id": 3073,
                "therapyName": "GSK690693",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18025,
                    "pubMedId": 28860825,
                    "title": "AKT inhibition is an effective treatment strategy in ARID1A-deficient gastric cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28860825"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20758,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK690693 in combination with Platinol (cisplatin) resulted in enhanced reduction in cell viability and induced apoptosis in ARID1A knockdown gastric cancer cell lines expressing AKT1 in culture (PMID: 28860825).",
            "molecularProfile": {
                "id": 35327,
                "profileName": "AKT1 pos ARID1A dec exp"
            },
            "therapy": {
                "id": 9442,
                "therapyName": "Cisplatin + GSK690693",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18025,
                    "pubMedId": 28860825,
                    "title": "AKT inhibition is an effective treatment strategy in ARID1A-deficient gastric cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28860825"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20759,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK690693 in combination with Adrucil (fluorouracil) resulted in enhanced reduction in cell viability and induced apoptosis in in ARID1A knockdown gastric cancer cell lines expressing AKT1 in culture (PMID: 28860825).",
            "molecularProfile": {
                "id": 35327,
                "profileName": "AKT1 pos ARID1A dec exp"
            },
            "therapy": {
                "id": 9441,
                "therapyName": "Fluorouracil + GSK690693",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18025,
                    "pubMedId": 28860825,
                    "title": "AKT inhibition is an effective treatment strategy in ARID1A-deficient gastric cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28860825"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20824,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, M802 inhibited growth of a gastric cancer cell line expressing high levels of ERBB2 (HER2) in culture, and inhibited tumor growth in xenograft models (PMID: 31412896).",
            "molecularProfile": {
                "id": 1270,
                "profileName": "ERBB2 over exp"
            },
            "therapy": {
                "id": 9489,
                "therapyName": "M802",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18082,
                    "pubMedId": 31412896,
                    "title": "A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31412896"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20825,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MBS301 inhibited proliferation of a gastric cancer cell line expressing high levels of ERBB2 (HER2) in culture, and inhibited tumor growth in xenograft models (PMID: 30081724).",
            "molecularProfile": {
                "id": 1270,
                "profileName": "ERBB2 over exp"
            },
            "therapy": {
                "id": 9493,
                "therapyName": "MBS301",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18091,
                    "pubMedId": 30081724,
                    "title": "Structural and functional characterization of MBS301, an afucosylated bispecific anti-HER2 antibody.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30081724"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21031,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, emergence of a KDM7A-BRAF fusion was identified as the mechanism mediating acquired AZD4547 resistance in a gastric cancer cell line harboring an FGFR2 amplification in culture (PMID: 30045926).",
            "molecularProfile": {
                "id": 35491,
                "profileName": "KDM7A - BRAF FGFR2 amp"
            },
            "therapy": {
                "id": 654,
                "therapyName": "AZD4547",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 18258,
                    "pubMedId": 30045926,
                    "title": "Acquired JHDM1D-BRAF Fusion Confers Resistance to FGFR Inhibition in FGFR2-Amplified Gastric Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30045926"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21032,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, gastric cancer cell lines harboring an FGFR2 amplification and a KDM7A-BRAF fusion demonstrated resistance to BGJ398 treatment in culture (PMID: 30045926).",
            "molecularProfile": {
                "id": 35491,
                "profileName": "KDM7A - BRAF FGFR2 amp"
            },
            "therapy": {
                "id": 674,
                "therapyName": "BGJ398",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 18258,
                    "pubMedId": 30045926,
                    "title": "Acquired JHDM1D-BRAF Fusion Confers Resistance to FGFR Inhibition in FGFR2-Amplified Gastric Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30045926"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21033,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, gastric cancer cell lines harboring an FGFR2 amplification and a KDM7A-BRAF fusion demonstrated resistance to PD173074 treatment in culture (PMID: 30045926).",
            "molecularProfile": {
                "id": 35491,
                "profileName": "KDM7A - BRAF FGFR2 amp"
            },
            "therapy": {
                "id": 2948,
                "therapyName": "PD173074",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 18258,
                    "pubMedId": 30045926,
                    "title": "Acquired JHDM1D-BRAF Fusion Confers Resistance to FGFR Inhibition in FGFR2-Amplified Gastric Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30045926"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21034,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, gastric cancer cell lines harboring an FGFR2 amplification and a KDM7A-BRAF fusion demonstrated resistance to Cediranib (AZD-2171) treatment in culture (PMID: 30045926).",
            "molecularProfile": {
                "id": 35491,
                "profileName": "KDM7A - BRAF FGFR2 amp"
            },
            "therapy": {
                "id": 1001,
                "therapyName": "Cediranib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 18258,
                    "pubMedId": 30045926,
                    "title": "Acquired JHDM1D-BRAF Fusion Confers Resistance to FGFR Inhibition in FGFR2-Amplified Gastric Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30045926"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21067,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, gastric cancer cell lines harboring an FGFR2 amplification and a KDM7A-BRAF fusion demonstrated decreased sensitivity to Zelboraf (vemurafenib) treatment in culture (PMID: 30045926).",
            "molecularProfile": {
                "id": 35491,
                "profileName": "KDM7A - BRAF FGFR2 amp"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 18258,
                    "pubMedId": 30045926,
                    "title": "Acquired JHDM1D-BRAF Fusion Confers Resistance to FGFR Inhibition in FGFR2-Amplified Gastric Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30045926"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 21068,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, gastric cancer cell lines harboring an FGFR2 amplification and a KDM7A-BRAF fusion demonstrated decreased sensitivity to PLX4720 treatment in culture (PMID: 30045926).",
            "molecularProfile": {
                "id": 35491,
                "profileName": "KDM7A - BRAF FGFR2 amp"
            },
            "therapy": {
                "id": 1060,
                "therapyName": "PLX4720",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 18258,
                    "pubMedId": 30045926,
                    "title": "Acquired JHDM1D-BRAF Fusion Confers Resistance to FGFR Inhibition in FGFR2-Amplified Gastric Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30045926"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 21083,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RO4987655 reduced Erk phosphorylation and inhibited growth of gastric cancer cell lines harboring an FGFR2 amplification and a KDM7A-BRAF fusion in culture (PMID: 30045926).",
            "molecularProfile": {
                "id": 35491,
                "profileName": "KDM7A - BRAF FGFR2 amp"
            },
            "therapy": {
                "id": 903,
                "therapyName": "RO4987655",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18258,
                    "pubMedId": 30045926,
                    "title": "Acquired JHDM1D-BRAF Fusion Confers Resistance to FGFR Inhibition in FGFR2-Amplified Gastric Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30045926"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21084,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) inhibited growth of gastric cancer cell lines harboring an FGFR2 amplification and a KDM7A-BRAF fusion in culture (PMID: 30045926).",
            "molecularProfile": {
                "id": 35491,
                "profileName": "KDM7A - BRAF FGFR2 amp"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18258,
                    "pubMedId": 30045926,
                    "title": "Acquired JHDM1D-BRAF Fusion Confers Resistance to FGFR Inhibition in FGFR2-Amplified Gastric Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30045926"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21085,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PD-0325901 inhibited growth of gastric cancer cell lines harboring an FGFR2 amplification and a KDM7A-BRAF fusion in culture (PMID: 30045926).",
            "molecularProfile": {
                "id": 35491,
                "profileName": "KDM7A - BRAF FGFR2 amp"
            },
            "therapy": {
                "id": 849,
                "therapyName": "PD-0325901",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18258,
                    "pubMedId": 30045926,
                    "title": "Acquired JHDM1D-BRAF Fusion Confers Resistance to FGFR Inhibition in FGFR2-Amplified Gastric Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30045926"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21086,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, gastric cancer cell lines harboring an FGFR2 amplification and a KDM7A-BRAF fusion were not sensitive to Pictilisib (GDC-0941) treatment in culture (PMID: 30045926).",
            "molecularProfile": {
                "id": 35491,
                "profileName": "KDM7A - BRAF FGFR2 amp"
            },
            "therapy": {
                "id": 749,
                "therapyName": "Pictilisib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 18258,
                    "pubMedId": 30045926,
                    "title": "Acquired JHDM1D-BRAF Fusion Confers Resistance to FGFR Inhibition in FGFR2-Amplified Gastric Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30045926"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21087,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a gastric cancer cell line harboring an FGFR2 amplification was not sensitive to Pictilisib (GDC-0941) treatment in culture (PMID: 30045926).",
            "molecularProfile": {
                "id": 3147,
                "profileName": "FGFR2 amp"
            },
            "therapy": {
                "id": 749,
                "therapyName": "Pictilisib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 18258,
                    "pubMedId": 30045926,
                    "title": "Acquired JHDM1D-BRAF Fusion Confers Resistance to FGFR Inhibition in FGFR2-Amplified Gastric Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30045926"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21088,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a gastric cancer cell line harboring an FGFR2 amplification was not sensitive to MK2206 treatment in culture (PMID: 30045926).",
            "molecularProfile": {
                "id": 3147,
                "profileName": "FGFR2 amp"
            },
            "therapy": {
                "id": 816,
                "therapyName": "MK2206",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 18258,
                    "pubMedId": 30045926,
                    "title": "Acquired JHDM1D-BRAF Fusion Confers Resistance to FGFR Inhibition in FGFR2-Amplified Gastric Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30045926"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21089,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, gastric cancer cell lines harboring an FGFR2 amplification and a KDM7A-BRAF fusion were not sensitive to MK2206 treatment in culture (PMID: 30045926).",
            "molecularProfile": {
                "id": 35491,
                "profileName": "KDM7A - BRAF FGFR2 amp"
            },
            "therapy": {
                "id": 816,
                "therapyName": "MK2206",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 18258,
                    "pubMedId": 30045926,
                    "title": "Acquired JHDM1D-BRAF Fusion Confers Resistance to FGFR Inhibition in FGFR2-Amplified Gastric Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30045926"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21090,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BGB659 inhibited growth of gastric cancer cell lines harboring an FGFR2 amplification and a KDM7A-BRAF fusion in culture (PMID: 30045926).",
            "molecularProfile": {
                "id": 35491,
                "profileName": "KDM7A - BRAF FGFR2 amp"
            },
            "therapy": {
                "id": 6245,
                "therapyName": "BGB659",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18258,
                    "pubMedId": 30045926,
                    "title": "Acquired JHDM1D-BRAF Fusion Confers Resistance to FGFR Inhibition in FGFR2-Amplified Gastric Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30045926"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21091,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZ628 reduced Erk phosphorylation and inhibited growth of gastric cancer cell lines harboring an FGFR2 amplification and a KDM7A-BRAF fusion in culture (PMID: 30045926).",
            "molecularProfile": {
                "id": 35491,
                "profileName": "KDM7A - BRAF FGFR2 amp"
            },
            "therapy": {
                "id": 1093,
                "therapyName": "AZ628",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18258,
                    "pubMedId": 30045926,
                    "title": "Acquired JHDM1D-BRAF Fusion Confers Resistance to FGFR Inhibition in FGFR2-Amplified Gastric Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30045926"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21092,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LY3009120 reduced Erk phosphorylation and inhibited growth of gastric cancer cell lines harboring an FGFR2 amplification and a KDM7A-BRAF fusion in culture (PMID: 30045926).",
            "molecularProfile": {
                "id": 35491,
                "profileName": "KDM7A - BRAF FGFR2 amp"
            },
            "therapy": {
                "id": 3268,
                "therapyName": "LY3009120",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18258,
                    "pubMedId": 30045926,
                    "title": "Acquired JHDM1D-BRAF Fusion Confers Resistance to FGFR Inhibition in FGFR2-Amplified Gastric Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30045926"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21099,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Capmatinib (INC280) did not induce tumor regression, however, inhibited tumor growth in an autocrine cell line xenograft model of gastric cancer overexpressing HGF (PMID: 30674502).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1065,
                "therapyName": "Capmatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 18298,
                    "pubMedId": 30674502,
                    "title": "Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30674502"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 21309,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a gastric cancer cell line harboring PIK3CA E545K was sensitive to treatment with Capivasertib (AZD5363), demonstrating decreased cell proliferation in culture (PMID: 32070411).",
            "molecularProfile": {
                "id": 2421,
                "profileName": "PIK3CA E545K"
            },
            "therapy": {
                "id": 655,
                "therapyName": "Capivasertib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18617,
                    "pubMedId": 32070411,
                    "title": "Comprehensive pharmacogenomic characterization of gastric cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/32070411"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21310,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, treatment with Capivasertib (AZD5363) in a patient with gastric cancer harboring PIK3CA E542K resulted in a partial response, and in preclinical studies, led to decreased cell proliferation in a gastric cancer cell line harboring PIK3CA E542K (PMID: 32070411).",
            "molecularProfile": {
                "id": 808,
                "profileName": "PIK3CA E542K"
            },
            "therapy": {
                "id": 655,
                "therapyName": "Capivasertib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18617,
                    "pubMedId": 32070411,
                    "title": "Comprehensive pharmacogenomic characterization of gastric cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/32070411"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT01037790",
            "title": "PHASE II TRIAL OF THE CYCLIN-DEPEDENT KINASE INHIBITOR PD 0332991 IN PATIENTS WITH CANCER",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 850,
                    "therapyName": "Palbociclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01148849",
            "title": "Safety Study of MGAH22 in HER2-positive Carcinomas",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 808,
                    "therapyName": "MGAH22",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01325441",
            "title": "A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2586,
                    "therapyName": "Napabucasin + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01468922",
            "title": "Pazopanib and ARQ 197 for Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 636,
                    "therapyName": "Tivantinib",
                    "synonyms": null
                },
                {
                    "id": 848,
                    "therapyName": "Pazopanib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01522768",
            "title": "Afatinib (BIBW 2992) and Trastuzumab in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1106,
                    "therapyName": "Afatinib + Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01576666",
            "title": "Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1547,
                    "therapyName": "Buparlisib + Sonidegib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01602406",
            "title": "Phase I Study LJM716 Combined With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast or Gastric Cancer",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2037,
                    "therapyName": "LJM716 + Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01641939",
            "title": "A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer",
            "phase": "Phase III",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 720,
                    "therapyName": "Docetaxel",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1402,
                    "therapyName": "Ado-trastuzumab emtansine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01702558",
            "title": "A Combination Study of Kadcyla (Trastuzumab Emtansine) and Capecitabine in Patients With HER2-Positive Metastatic Breast Cancer and Patients With HER2-Positive Locally Advanced / Metastatic Gastric Cancer",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1402,
                    "therapyName": "Ado-trastuzumab emtansine",
                    "synonyms": null
                },
                {
                    "id": 1976,
                    "therapyName": "Ado-trastuzumab emtansine + Capecitabine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01928290",
            "title": "Combination Chemotherapy in Treating Patients With Advanced Stomach, Gastroesophageal, or Esophageal Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 947,
                    "therapyName": "Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 1903,
                    "therapyName": "Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin",
                    "synonyms": "FOLFIRINOX|FOLFOXIRI"
                }
            ]
        },
        {
            "nctId": "NCT01928394",
            "title": "Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1627,
                    "therapyName": "Ipilimumab + Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 8260,
                    "therapyName": "Cobimetinib + Ipilimumab + Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01938638",
            "title": "Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 4027,
                    "therapyName": "BAY1143572",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01968109",
            "title": "Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4197,
                    "therapyName": "Nivolumab + Relatlimab",
                    "synonyms": null
                },
                {
                    "id": 4196,
                    "therapyName": "Relatlimab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01989546",
            "title": "Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 682,
                    "therapyName": "Talazoparib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02014909",
            "title": "A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2054,
                    "therapyName": "CDX-3379",
                    "synonyms": null
                },
                {
                    "id": 2063,
                    "therapyName": "CDX-3379 + Vemurafenib",
                    "synonyms": null
                },
                {
                    "id": 2064,
                    "therapyName": "CDX-3379 + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 2061,
                    "therapyName": "CDX-3379 + Cetuximab",
                    "synonyms": null
                },
                {
                    "id": 2062,
                    "therapyName": "CDX-3379 + Erlotinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02047747",
            "title": "A Phase II Study of Dacomitinib in Progressive Brain Metastases",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 714,
                    "therapyName": "Dacomitinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02122809",
            "title": "Phase I Study of Chiauranib in Patients With Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1998,
                    "therapyName": "Chiauranib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02178722",
            "title": "A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination With Epacadostat (INCB024360) in Subjects With Selected Cancers (INCB 24360-202 / MK-3475-037 / KEYNOTE-037/ ECHO-202)",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 4088,
                    "therapyName": "Epacadostat + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02281409",
            "title": "Safety, Tolerability, and Immunoregulatory Activity of Mogamulizumab (KW-0761) in Subjects With Advanced and/or Metastatic Solid Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2968,
                    "therapyName": "Mogamulizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02310464",
            "title": "Trial of Active Immunotherapy With OBI-833 (Globo H-CRM197) in Advanced/Metastatic Gastric, Lung, Colorectal or Breast Cancer Subjects",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7271,
                    "therapyName": "OBI-821 + OBI-833",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02314117",
            "title": "A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1105,
                    "therapyName": "Capecitabine",
                    "synonyms": null
                },
                {
                    "id": 1715,
                    "therapyName": "Fluorouracil",
                    "synonyms": null
                },
                {
                    "id": 700,
                    "therapyName": "Cisplatin",
                    "synonyms": null
                },
                {
                    "id": 886,
                    "therapyName": "Ramucirumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02315066",
            "title": "Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 4333,
                    "therapyName": "PF-04518600",
                    "synonyms": null
                },
                {
                    "id": 4448,
                    "therapyName": "PF-04518600 + Utomilumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02318901",
            "title": "Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1909,
                    "therapyName": "Ado-trastuzumab emtansine + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 1908,
                    "therapyName": "Pembrolizumab + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 1910,
                    "therapyName": "Cetuximab + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02323191",
            "title": "A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 7438,
                    "therapyName": "Atezolizumab + Emactuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02341625",
            "title": "A Study of BMS-986148 in Patients With Select Advanced Solid Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 4923,
                    "therapyName": "BMS-986148",
                    "synonyms": null
                },
                {
                    "id": 4924,
                    "therapyName": "BMS-986148 + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02346955",
            "title": "Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001)",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 4246,
                    "therapyName": "CM-24",
                    "synonyms": null
                },
                {
                    "id": 4247,
                    "therapyName": "CM-24 + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02393248",
            "title": "Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4176,
                    "therapyName": "Cisplatin + Gemcitabine + Pemigatinib",
                    "synonyms": null
                },
                {
                    "id": 4174,
                    "therapyName": "Docetaxel + Pemigatinib",
                    "synonyms": null
                },
                {
                    "id": 8250,
                    "therapyName": "INCMGA00012 + Pemigatinib",
                    "synonyms": null
                },
                {
                    "id": 8249,
                    "therapyName": "Pemigatinib + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 4088,
                    "therapyName": "Epacadostat + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02404441",
            "title": "Phase I/II Study of PDR001 in Patients With Advanced Malignancies",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2659,
                    "therapyName": "Spartalizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02443883",
            "title": "A Phase 2 Study of Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) Cancer",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 886,
                    "therapyName": "Ramucirumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02452424",
            "title": "A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 2736,
                    "therapyName": "Pembrolizumab + Pexidartinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02460224",
            "title": "Safety and Efficay of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2887,
                    "therapyName": "LAG525",
                    "synonyms": null
                },
                {
                    "id": 2659,
                    "therapyName": "Spartalizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02471846",
            "title": "A Study of GDC-0919 and MPDL3280A Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2888,
                    "therapyName": "GDC-0919",
                    "synonyms": null
                },
                {
                    "id": 1201,
                    "therapyName": "Atezolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02500199",
            "title": "Open Label Oral Use of Pyrotinib in Patients With HER2 Positive Solid Tumors Who Failed Prior HER2 Targeted Therapy",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3082,
                    "therapyName": "Pyrotinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02554812",
            "title": "A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6045,
                    "therapyName": "Avelumab + PF-04518600",
                    "synonyms": null
                },
                {
                    "id": 8286,
                    "therapyName": "Avelumab + PD 0360324",
                    "synonyms": null
                },
                {
                    "id": 6043,
                    "therapyName": "Avelumab + Utomilumab",
                    "synonyms": null
                },
                {
                    "id": 6044,
                    "therapyName": "Avelumab + PF-04518600 + Utomilumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02559492",
            "title": "INCB039110 Combined With INCB024360 and/or INCB039110 Combined With INCB050465 in Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 3096,
                    "therapyName": "Epacadostat + Itacitinib",
                    "synonyms": null
                },
                {
                    "id": 3097,
                    "therapyName": "Itacitinib + Parsaclisib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02575781",
            "title": "A Study of SAR428926 in Patients With Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 4026,
                    "therapyName": "SAR428926",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02631733",
            "title": "Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery",
            "phase": "Phase I",
            "recruitment": "Suspended",
            "therapies": [
                {
                    "id": 3314,
                    "therapyName": "Irinotecan + Veliparib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02646748",
            "title": "Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 7159,
                    "therapyName": "Itacitinib + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 8295,
                    "therapyName": "Parsaclisib + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02658214",
            "title": "Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 8330,
                    "therapyName": "Cisplatin + Durvalumab + Fluorouracil + Tremelimumab",
                    "synonyms": null
                },
                {
                    "id": 8329,
                    "therapyName": "Durvalumab + Gemcitabine + Nab-paclitaxel + Tremelimumab",
                    "synonyms": null
                },
                {
                    "id": 8328,
                    "therapyName": "Durvalumab + Fluorouracil + Leucovorin + Oxaliplatin + Tremelimumab",
                    "synonyms": null
                },
                {
                    "id": 8327,
                    "therapyName": "Carboplatin + Durvalumab + Nab-paclitaxel + Tremelimumab",
                    "synonyms": null
                },
                {
                    "id": 8326,
                    "therapyName": "Carboplatin + Durvalumab + Etoposide + Tremelimumab",
                    "synonyms": null
                },
                {
                    "id": 8325,
                    "therapyName": "Carboplatin + Durvalumab + Paclitaxel + Tremelimumab",
                    "synonyms": null
                },
                {
                    "id": 7524,
                    "therapyName": "Carboplatin + Durvalumab + Gemcitabine + Tremelimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02660034",
            "title": "The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Subjects With Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5883,
                    "therapyName": "BGB-A317 + Pamiparib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02734004",
            "title": "A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. (MEDIOLA)",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2894,
                    "therapyName": "Durvalumab + Olaparib",
                    "synonyms": null
                },
                {
                    "id": 7490,
                    "therapyName": "Bevacizumab + Durvalumab + Olaparib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02760797",
            "title": "A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 4181,
                    "therapyName": "Emactuzumab + RO7009789",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02824042",
            "title": "Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 4594,
                    "therapyName": "Anetumab ravtansine + Itraconazole",
                    "synonyms": null
                },
                {
                    "id": 4593,
                    "therapyName": "Anetumab ravtansine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02872116",
            "title": "Efficacy Study of Nivolumab Plus Ipilimumab Against Chemotherapy Standard of Care in Stomach Cancer or Stomach/Esophagus Junction Cancer (CheckMate649)",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1597,
                    "therapyName": "Capecitabine + Oxaliplatin",
                    "synonyms": null
                },
                {
                    "id": 1627,
                    "therapyName": "Ipilimumab + Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 1161,
                    "therapyName": "Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02880371",
            "title": "A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 4608,
                    "therapyName": "ARRY-382 + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02900651",
            "title": "Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9055,
                    "therapyName": "MAK683",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02935634",
            "title": "A Study to Test Combination Treatments in Patients With Advanced Gastric Cancer (FRACTION-GC)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4197,
                    "therapyName": "Nivolumab + Relatlimab",
                    "synonyms": null
                },
                {
                    "id": 1627,
                    "therapyName": "Ipilimumab + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02952248",
            "title": "A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid Tumours",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5692,
                    "therapyName": "BI 754091",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02952729",
            "title": "Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 5834,
                    "therapyName": "XMT-1522",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02960594",
            "title": "hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 5844,
                    "therapyName": "INO-1400 + INO-9012",
                    "synonyms": null
                },
                {
                    "id": 5807,
                    "therapyName": "INO-1400",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02963831",
            "title": "A Phase 1/2 Study to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4978,
                    "therapyName": "Durvalumab + ONCOS-102",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02965885",
            "title": "A Study of TAS-116 in Patients With Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2768,
                    "therapyName": "TAS-116",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02970539",
            "title": "Ph1b Study of Oraxol in Comb. w. Ramucirumab in Patients w. Gastric, Gastro-esophageal, or Esophageal Cancers",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5032,
                    "therapyName": "Oraxol + Ramucirumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03126110",
            "title": "Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5599,
                    "therapyName": "INCAGN01876 + Ipilimumab + Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 5598,
                    "therapyName": "INCAGN01876 + Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 5597,
                    "therapyName": "INCAGN01876 + Ipilimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03132922",
            "title": "MAGE-A4c1032T for Multi-Tumor",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7280,
                    "therapyName": "ADP-A2M4 cells",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03284723",
            "title": "PF-06804103 Dose Escalation in HER2 Positive Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7359,
                    "therapyName": "PF-06804103",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03319459",
            "title": "FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 6375,
                    "therapyName": "FATE-NK100",
                    "synonyms": null
                },
                {
                    "id": 6376,
                    "therapyName": "FATE-NK100 + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 6377,
                    "therapyName": "Cetuximab + FATE-NK100",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03329950",
            "title": "A Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7361,
                    "therapyName": "CDX-1140 + CDX-301",
                    "synonyms": null
                },
                {
                    "id": 7330,
                    "therapyName": "CDX-1140",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03330561",
            "title": "PRS-343 in HER2-Positive Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6437,
                    "therapyName": "PRS-343",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03342417",
            "title": "Combination of Nivolumab and Ipilimumab in Breast, Ovarian and Gastric Cancer Patients",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1627,
                    "therapyName": "Ipilimumab + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03410927",
            "title": "A Study of TAS0728 in Patients With Solid Tumors With HER2 or HER3 Abnormalities",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 8170,
                    "therapyName": "TAS0728",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03416335",
            "title": "A Study of DSP-0509 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8822,
                    "therapyName": "DSP-0509",
                    "synonyms": null
                },
                {
                    "id": 8823,
                    "therapyName": "DSP-0509 + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03448042",
            "title": "A Phase I Study of BTRC4017A in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7807,
                    "therapyName": "BTRC 4017A",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03511222",
            "title": "Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6917,
                    "therapyName": "Pembrolizumab + Vorolanib",
                    "synonyms": null
                },
                {
                    "id": 6916,
                    "therapyName": "Nivolumab + Vorolanib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03538028",
            "title": "A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6977,
                    "therapyName": "INCAGN02385",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03568539",
            "title": "IBI308 in Subjects With Advanced/Metastatic Solid Malignancies",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 6138,
                    "therapyName": "Sintilimab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03596372",
            "title": "Study of BAY1834942 in Patients With Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7305,
                    "therapyName": "BAY1834942",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03602079",
            "title": "Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7810,
                    "therapyName": "A166",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03610711",
            "title": "REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer (REACTION)",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4197,
                    "therapyName": "Nivolumab + Relatlimab",
                    "synonyms": null
                },
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03621982",
            "title": "Study of ADCT-301 in Patients With Selected Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7369,
                    "therapyName": "Camidanlumab Tesirine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03629756",
            "title": "A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8016,
                    "therapyName": "AB928 + GLS-010",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03662659",
            "title": "An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 7474,
                    "therapyName": "Nivolumab + Relatlimab + TS-1",
                    "synonyms": null
                },
                {
                    "id": 7473,
                    "therapyName": "Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin + Relatlimab",
                    "synonyms": "Nivolumab + Relatlimab + FOLFOX"
                },
                {
                    "id": 7476,
                    "therapyName": "Nivolumab + TS-1",
                    "synonyms": null
                },
                {
                    "id": 7475,
                    "therapyName": "Capecitabine + Nivolumab + Oxaliplatin",
                    "synonyms": null
                },
                {
                    "id": 7184,
                    "therapyName": "Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin",
                    "synonyms": "Nivolumab + FOLFOX"
                },
                {
                    "id": 7472,
                    "therapyName": "Capecitabine + Nivolumab + Oxaliplatin + Relatlimab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03674567",
            "title": "Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7533,
                    "therapyName": "FLX475 + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 7530,
                    "therapyName": "FLX475",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03694249",
            "title": "Ifetroban in Treating Patients With Malignant Solid Tumors at High Risk of Metastatic Recurrence",
            "phase": "Phase II",
            "recruitment": "Suspended",
            "therapies": [
                {
                    "id": 9193,
                    "therapyName": "Ifetroban sodium",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03700294",
            "title": "Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Suspended",
            "therapies": [
                {
                    "id": 7566,
                    "therapyName": "ADCT-601",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03704077",
            "title": "An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Trherapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cance or Gastroesophageal Junction Adenocarcinoma",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 1721,
                    "therapyName": "Paclitaxel + Ramucirumab",
                    "synonyms": null
                },
                {
                    "id": 7433,
                    "therapyName": "Nivolumab + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 7431,
                    "therapyName": "Nivolumab + Paclitaxel + Relatlimab",
                    "synonyms": null
                },
                {
                    "id": 4197,
                    "therapyName": "Nivolumab + Relatlimab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03720678",
            "title": "A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Gastrointestinal (GI) Malignancies",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7575,
                    "therapyName": "AB928 + Fluorouracil + Leucovorin + Oxaliplatin",
                    "synonyms": "AB928 + FOLFOX"
                }
            ]
        },
        {
            "nctId": "NCT03797326",
            "title": "Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 4782,
                    "therapyName": "Lenvatinib + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03816345",
            "title": "Nivolumab in Treating Patients With Autoimmune Disorders or Advanced, Metastatic, or Unresectable Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03829501",
            "title": "Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7826,
                    "therapyName": "Atezolizumab + KY1044",
                    "synonyms": null
                },
                {
                    "id": 7825,
                    "therapyName": "KY1044",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03847168",
            "title": "KN026 in Patients With HER2 Expressing Breast Cancer and Gastric Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9490,
                    "therapyName": "KN026",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03872947",
            "title": "A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8046,
                    "therapyName": "Pembrolizumab + TRK-950",
                    "synonyms": null
                },
                {
                    "id": 8078,
                    "therapyName": "Carboplatin + Gemcitabine + TRK-950",
                    "synonyms": null
                },
                {
                    "id": 8047,
                    "therapyName": "Imiquimod + TRK-950",
                    "synonyms": null
                },
                {
                    "id": 8079,
                    "therapyName": "Paclitaxel + Ramucirumab + TRK-950",
                    "synonyms": null
                },
                {
                    "id": 8045,
                    "therapyName": "Nivolumab + TRK-950",
                    "synonyms": null
                },
                {
                    "id": 8077,
                    "therapyName": "Cisplatin + Gemcitabine + TRK-950",
                    "synonyms": null
                },
                {
                    "id": 8043,
                    "therapyName": "Fluorouracil + Irinotecan + Leucovorin + TRK-950",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03936959",
            "title": "A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 9537,
                    "therapyName": "LY3434172",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03973333",
            "title": "Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8448,
                    "therapyName": "Atezolizumab + IMC-C103C",
                    "synonyms": null
                },
                {
                    "id": 8447,
                    "therapyName": "IMC-C103C",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03993873",
            "title": "Phase 1 Study of TPX-0022, a MET/CSF1R/SRC Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in MET",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8205,
                    "therapyName": "TPX-0022",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04014075",
            "title": "DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4844,
                    "therapyName": "Fam-trastuzumab deruxtecan-nxki",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04044859",
            "title": "Surpass: ADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 Positive Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9445,
                    "therapyName": "ADP-A2M4CD8 cells",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04060342",
            "title": "GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8693,
                    "therapyName": "GB1275",
                    "synonyms": null
                },
                {
                    "id": 8694,
                    "therapyName": "GB1275 + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 8695,
                    "therapyName": "GB1275 + Gemcitabine + Nab-paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04082364",
            "title": "Combination Margetuximab, INCMGA00012, MGD013, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer (MAHOGANY)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9725,
                    "therapyName": "Fluorouracil + Leucovorin + MGAH22 + Oxaliplatin",
                    "synonyms": null
                },
                {
                    "id": 3439,
                    "therapyName": "Fluorouracil + Leucovorin + Oxaliplatin + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 9720,
                    "therapyName": "Capecitabine + INCMGA00012 + MGAH22 + Oxaliplatin",
                    "synonyms": null
                },
                {
                    "id": 9719,
                    "therapyName": "INCMGA00012 + MGAH22",
                    "synonyms": null
                },
                {
                    "id": 9722,
                    "therapyName": "Capecitabine + MGAH22 + MGD013 + Oxaliplatin",
                    "synonyms": null
                },
                {
                    "id": 7514,
                    "therapyName": "Capecitabine + Oxaliplatin + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 9721,
                    "therapyName": "Fluorouracil + INCMGA00012 + Leucovorin + MGAH22 + Oxaliplatin",
                    "synonyms": null
                },
                {
                    "id": 9724,
                    "therapyName": "Capecitabine + MGAH22 + Oxaliplatin",
                    "synonyms": null
                },
                {
                    "id": 9723,
                    "therapyName": "Fluorouracil + Leucovorin + MGAH22 + MGD013 + Oxaliplatin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04095273",
            "title": "Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the ATR Inhibitor BAY1895344 in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8754,
                    "therapyName": "BAY1895344 + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04147819",
            "title": "A First in Human Study of BAY2701439 to Look at Safety, How the Body Absorbs, Distributes and Excretes the Drug, and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 Protein",
            "phase": "Phase I",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 9606,
                    "therapyName": "BAY2701439",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04152018",
            "title": "Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8931,
                    "therapyName": "PF-06801591 + PF-06940434",
                    "synonyms": null
                },
                {
                    "id": 8930,
                    "therapyName": "PF-06940434",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04189445",
            "title": "Futibatinib in Patients With Specific FGFR Aberrations",
            "phase": "Phase II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 1053,
                    "therapyName": "Futibatinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04209686",
            "title": "Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma",
            "phase": "Phase II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 7701,
                    "therapyName": "Olaparib + Paclitaxel + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04225117",
            "title": "A Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4125,
                    "therapyName": "Enfortumab vedotin-ejfv",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04250597",
            "title": "Study of GNX102 in Patients With Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 9331,
                    "therapyName": "GNX102",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04259450",
            "title": "Study to Assess AFM24 in Advanced Solid Cancers",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5856,
                    "therapyName": "AFM24",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04260802",
            "title": "A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers",
            "phase": "Phase Ib/II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 9335,
                    "therapyName": "OC-001 + unspecified PD-L1 antibody",
                    "synonyms": null
                },
                {
                    "id": 9334,
                    "therapyName": "OC-001 + unspecified PD-1 antibody",
                    "synonyms": null
                },
                {
                    "id": 9333,
                    "therapyName": "OC-001",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04294576",
            "title": "Safety Study of BJ-001, and IL-15 Fusion Protein, for Locally Advanced/Metastatic Solid Tumors (FIH)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9460,
                    "therapyName": "BJ-001 + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 9459,
                    "therapyName": "BJ-001",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04319757",
            "title": "ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 9764,
                    "therapyName": "ACE1702 + Cyclophosphamide + Fludarabine",
                    "synonyms": null
                }
            ]
        }
    ]
}